ICU Medical (ICUI) 10-Q 7 Nov 22 2022 Q3 Quarterly report Financial data

DEI Document

DEI Document - shares	9 Months Ended
	Sep. 30, 2022	Oct. 31, 2022
Document And Entity Information [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2022
Document Transition Report	false
Entity File Number	001-34634
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	33-0022692
Entity Address, Address Line One	951 Calle Amanecer
Entity Address, City or Town	San Clemente
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	92673
City Area Code	949
Local Phone Number	366-2183
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Title of 12(b) Security	Common stock, par value $0.10 per share
Trading Symbol	ICUI
Security Exchange Name	NASDAQ
Entity Common Stock, Shares Outstanding		23,981,588
Entity Central Index Key	0000883984
Entity Registrant Name	ICU MEDICAL INC/DE
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q3

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
CURRENT ASSETS:
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents	$ 243,879	$ 552,827	[1]
Short-term investment securities	2,919	14,420	[1]
TOTAL CASH, CASH EQUIVALENTS AND INVESTMENT SECURITIES	246,798	567,247	[1]
Accounts receivable, net of allowance for doubtful accounts	212,845	105,894	[1]
Inventories	625,268	290,235	[1]
Prepaid income taxes	20,170	19,586	[1]
Prepaid expenses and other current assets	94,283	46,847	[1]
TOTAL CURRENT ASSETS	1,199,364	1,029,809	[1]
PROPERTY AND EQUIPMENT, net	656,383	468,365	[1]
Operating Lease, Right-of-Use Asset	76,438	39,847	[1]
Long-term investment securities	1,831	4,620
GOODWILL	1,369,717	43,439	[1]
INTANGIBLE ASSETS, net	1,020,658	188,311	[1]
Deferred Income Tax Assets	15,482	42,604
OTHER ASSETS	110,604	63,743	[1]
TOTAL ASSETS	4,450,477	1,880,738	[1]
CURRENT LIABILITIES:
Accounts payable	205,042	81,128	[1]
Accrued liabilities	244,303	118,195	[1]
Long-term Debt, Current Maturities	24,375	0
Income tax liability	15,014	1,454	[1]
Contingent earn-out liability	300	0
TOTAL CURRENT LIABILITIES	489,034	200,777	[1]
Contingent Earn-Out Liability, Noncurrent	25,942	2,589	[1]
Long-term Debt, Excluding Current Maturities	1,629,849	0
Other long-term liabilities	119,251	41,830
DEFERRED INCOME TAXES	153,599	1,490	[1]
INCOME TAX LIABILITY	19,997	18,021	[1]
COMMITMENTS AND CONTINGENCIES	0	0	[1]
STOCKHOLDERS' EQUITY:
Convertible preferred stock, $1.00 par value Authorized-500 shares; Issued and outstanding - none	0	0	[1]
Common stock, $0.10 par value - Authorized-80,000 shares; Issued 23,899 shares at June 30,2022 and 21,280 shares at December 31, 2021 and outstanding 23,898 shares at June 30, 2022 and 21,280 shares at December 31, 2021	2,398	2,128	[1]
Additional paid-in capital	1,323,178	721,412	[1]
Treasury Stock, at cost (12,684 and 119 shares, respectively)	(126)	(27)	[1]
Retained earnings	853,037	911,787	[1]
Accumulated other comprehensive loss	(165,682)	(19,269)	[1]
TOTAL STOCKHOLDERS' EQUITY	2,012,805	1,616,031	[1]
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 4,450,477	$ 1,880,738	[1]
[1]December 31, 2021 balances were derived from audited consolidated financial statements.

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Accounts Receivable, Allowance for Credit Loss	$ 8,006	$ 7,038
Convertible preferred stock, par value	$ 1
Convertible preferred stock, authorized shares	500,000
Convertible preferred stock, issued shares	0	0
Convertible preferred stock, outstanding shares	0	0
Common stock, par value	$ 0.10
Common stock, shares authorized	80,000,000
Common stock, shares issued	23,980,000	21,280,000
Common stock, shares outstanding	23,979,000	21,280,000
Treasury Stock, Shares	712	119

Condensed Consolidated Statemen

Condensed Consolidated Statements of Income - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
REVENUES:
Revenue from Contract with Customer, Excluding Assessed Tax	$ 597,857	$ 336,060	$ 1,701,983	$ 975,783
Cost of goods sold	411,461	208,269	1,179,167	611,783
Gross Profit	186,396	127,791	522,816	364,000
OPERATING EXPENSES:
Selling, general and administrative	153,452	74,815	465,412	221,127
Research and development	23,105	12,238	69,538	34,332
Restructuring, strategic transaction and integration	14,365	2,358	61,795	8,994
Change in fair value of contingent earn-out	(4,059)	0	(31,253)	0
contract settlement	0	0	0	127
TOTAL OPERATING EXPENSES	186,863	89,411	565,492	264,580
(LOSS) INCOME FROM OPERATIONS	(467)	38,380	(42,676)	99,420
Interest Expense	(21,151)	(168)	(51,068)	(492)
OTHER (EXPENSE) INCOME, net	311	(287)	782	921
(Loss) Income from Continuing Operations before Income Taxes, Noncontrolling Interest	(21,307)	37,925	(92,962)	99,849
BENEFIT (PROVISION) FOR INCOME TAXES	8,099	(6,844)	34,212	(16,639)
NET (LOSS) INCOME	$ (13,208)	$ 31,081	$ (58,750)	$ 83,210
NET INCOME PER SHARE
Basic (in dollars per share)	$ (0.55)	$ 1.47	$ (2.47)	$ 3.93
Diluted (in dollars per share)	$ (0.55)	$ 1.43	$ (2.47)	$ 3.83
WEIGHTED AVERAGE NUMBER OF SHARES
Basic (in shares)	23,908	21,214	23,828	21,189
Diluted (in shares)	23,908	21,730	23,828	21,735

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Comprehensive Income - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Net (Loss) Income	$ (13,208)	$ 31,081	$ (58,750)	$ 83,210
Other comprehensive income (loss), net of tax
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax	16,915	(819)	48,631	(2,116)
Foreign currency translation adjustment, net of taxes of $0 for all periods	(90,549)	(5,360)	(195,300)	(11,516)
Other Comprehensive Income (Loss), Other Adjustments, after Tax	227	12	256	36
Other comprehensive income (loss), net of taxes	(73,407)	(6,167)	(146,413)	(13,596)
Comprehensive Income	$ (86,615)	$ 24,914	$ (205,163)	$ 69,614

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Comprehensive Income (Paranthetical) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Statement of Comprehensive Income [Abstract]
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax	$ (3,676)	$ 259	$ (15,357)	$ 668
Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax	0	0	0	0
Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, Tax	$ 0	$ 0	$ 0	$ 0

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Stockholders' Equity Statement - USD ($) $ in Thousands	Total	Common Stock Shares [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Treasury Stock [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]
Common stock, shares outstanding at Dec. 31, 2020		21,058,000
Stockholders' Equity Attributable to Parent at Dec. 31, 2020	$ 1,502,265		$ 2,106	$ 693,068	$ (39)	$ 808,652	$ (1,522)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock Issued During Period, Shares, New Issues		198,000
Stock Issued During Period, Value, New Issues	4,864		16		2,352
Adjustments to Additional Paid in Capital, Other				2,496
Share-based Payment Arrangement, Shares Withheld for Tax Withholding Obligation		(37,000)
Share-based Payment Arrangement, Decrease for Tax Withholding Obligation	(7,723)				(7,723)
APIC, Share-based Payment Arrangement, Increase for Cost Recognition	6,022			6,022
Other Comprehensive (Loss) Income, Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax	(8,391)
Net Income Attributable to Parent	23,731					23,731
Stockholders' Equity Attributable to Parent at Mar. 31, 2021	1,520,768		2,122	701,586	(5,410)	832,383	(9,913)
Common stock, shares outstanding at Mar. 31, 2021		21,219,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Other Comprehensive income (loss), net of Tax	(8,391)						(8,391)
Common stock, shares outstanding at Dec. 31, 2020		21,058,000
Stockholders' Equity Attributable to Parent at Dec. 31, 2020	$ 1,502,265		2,106	693,068	(39)	808,652	(1,522)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Share-based Payment Arrangement, Shares Withheld for Tax Withholding Obligation	(39,371)
Stockholders' Equity Attributable to Parent at Sep. 30, 2021	$ 1,589,972		2,124	711,152	(48)	891,862	(15,118)
Common stock, shares outstanding at Sep. 30, 2021		21,238,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Other Comprehensive income (loss), net of Tax	(13,596)
Common stock, shares outstanding at Mar. 31, 2021		21,219,000
Stockholders' Equity Attributable to Parent at Mar. 31, 2021	1,520,768		2,122	701,586	(5,410)	832,383	(9,913)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock Issued During Period, Shares, New Issues		0
Stock Issued During Period, Value, New Issues	552		0		3,237
Adjustments to Additional Paid in Capital, Other				(2,685)
Share-based Payment Arrangement, Shares Withheld for Tax Withholding Obligation		0
Share-based Payment Arrangement, Decrease for Tax Withholding Obligation	(96)				(96)
APIC, Share-based Payment Arrangement, Increase for Cost Recognition	6,681			6,681
Other Comprehensive (Loss) Income, Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax	962
Net Income Attributable to Parent	28,398					28,398
Stockholders' Equity Attributable to Parent at Jun. 30, 2021	1,557,265		2,122	705,582	(2,269)	860,781	(8,951)
Common stock, shares outstanding at Jun. 30, 2021		21,219,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Other Comprehensive income (loss), net of Tax	962						962
Stock Issued During Period, Shares, New Issues		20,000
Stock Issued During Period, Value, New Issues	1,550		2		2,511
Adjustments to Additional Paid in Capital, Other				(963)
Share-based Payment Arrangement, Shares Withheld for Tax Withholding Obligation		(1,000)
Share-based Payment Arrangement, Decrease for Tax Withholding Obligation	(290)				(290)
APIC, Share-based Payment Arrangement, Increase for Cost Recognition	6,533			6,533
Other Comprehensive (Loss) Income, Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax	(6,167)
Net Income Attributable to Parent	31,081					31,081
Stockholders' Equity Attributable to Parent at Sep. 30, 2021	1,589,972		2,124	711,152	(48)	891,862	(15,118)
Common stock, shares outstanding at Sep. 30, 2021		21,238,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Other Comprehensive income (loss), net of Tax	$ (6,167)						(6,167)
Common stock, shares outstanding at Dec. 31, 2021	21,280,000	21,280,000
Stockholders' Equity Attributable to Parent at Dec. 31, 2021	$ 1,616,031		2,128	721,412	(27)	911,787	(19,269)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock Issued During Period, Shares, New Issues		154,000
Stock Issued During Period, Value, New Issues	2,974		12		5,927
Adjustments to Additional Paid in Capital, Other				(2,965)
Share-based Payment Arrangement, Shares Withheld for Tax Withholding Obligation		(37,000)
Share-based Payment Arrangement, Decrease for Tax Withholding Obligation	(8,743)				(8,743)
Stock Issued During Period, Value, Acquisitions	$ 575,975		250	575,725
Stock Issued During Period, Shares, Acquisitions	2,500,000
APIC, Share-based Payment Arrangement, Increase for Cost Recognition	$ 12,092			12,092
Other Comprehensive (Loss) Income, Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax	18,641
Net Income Attributable to Parent	(38,068)					(38,068)
Stockholders' Equity Attributable to Parent at Mar. 31, 2022	2,178,902		2,390	1,306,264	(2,843)	873,719	(628)
Common stock, shares outstanding at Mar. 31, 2022		23,897,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Other Comprehensive income (loss), net of Tax	$ 18,641						18,641
Common stock, shares outstanding at Dec. 31, 2021	21,280,000	21,280,000
Stockholders' Equity Attributable to Parent at Dec. 31, 2021	$ 1,616,031		2,128	721,412	(27)	911,787	(19,269)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Share-based Payment Arrangement, Shares Withheld for Tax Withholding Obligation	(45,370)
Stockholders' Equity Attributable to Parent at Sep. 30, 2022	$ 2,012,805		2,398	1,323,178	(126)	853,037	(165,682)
Common stock, shares outstanding at Sep. 30, 2022	23,979,000	23,979,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Other Comprehensive income (loss), net of Tax	$ (146,413)
Common stock, shares outstanding at Mar. 31, 2022		23,897,000
Stockholders' Equity Attributable to Parent at Mar. 31, 2022	2,178,902		2,390	1,306,264	(2,843)	873,719	(628)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock Issued During Period, Shares, New Issues		10,000
Stock Issued During Period, Value, New Issues	18		0		4,446
Adjustments to Additional Paid in Capital, Other				(4,428)
Share-based Payment Arrangement, Shares Withheld for Tax Withholding Obligation		(8,000)
Share-based Payment Arrangement, Decrease for Tax Withholding Obligation	(1,695)				(1,695)
APIC, Share-based Payment Arrangement, Increase for Cost Recognition	7,762			7,762
Other Comprehensive (Loss) Income, Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax	(91,647)
Net Income Attributable to Parent	(7,474)					(7,474)
Stockholders' Equity Attributable to Parent at Jun. 30, 2022	2,085,866		2,390	1,309,598	(92)	866,245	(92,275)
Common stock, shares outstanding at Jun. 30, 2022		23,899,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Other Comprehensive income (loss), net of Tax	(91,647)						(91,647)
Stock Issued During Period, Shares, New Issues		82,000
Stock Issued During Period, Value, New Issues	4,914		8		69
Adjustments to Additional Paid in Capital, Other				4,837
Share-based Payment Arrangement, Shares Withheld for Tax Withholding Obligation		(2,000)
Share-based Payment Arrangement, Decrease for Tax Withholding Obligation	(103)				(103)
APIC, Share-based Payment Arrangement, Increase for Cost Recognition	8,743			8,743
Other Comprehensive (Loss) Income, Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax	(73,407)
Net Income Attributable to Parent	(13,208)					(13,208)
Stockholders' Equity Attributable to Parent at Sep. 30, 2022	$ 2,012,805		$ 2,398	$ 1,323,178	$ (126)	$ 853,037	(165,682)
Common stock, shares outstanding at Sep. 30, 2022	23,979,000	23,979,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Other Comprehensive income (loss), net of Tax	$ (73,407)						$ (73,407)

Condensed Consolidated Statem_5

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
CASH FLOWS FROM OPERATING ACTIVITIES:
Net (Loss) Income	$ (58,750)	$ 83,210
Depreciation and amortization	178,338	66,564
Amortization of Inventory Step-up	22,676	0
Noncash lease expense	17,382	7,165
Provision for doubtful accounts	214	342
Provision for warranty and returns	3,439	752
Stock compensation	28,597	19,236
Loss on disposal of property and equipment	2,391	1,083
Bond premium amortization	254	514
Debt Issuance Costs amortization	5,254	216
Change in fair value of contingent earn-out	(31,253)	0
Inventory Recall Expense	0	3,380
Sparepartsusage	7,915	9,831
Other Noncash Income (Expense)	(2,855)	2,908
Accounts receivable	(8,956)	3,807
Inventories	(151,840)	16,510
Prepaid expenses and other assets	20,074	3,557
Increase (Decrease) in Other Operating Assets	(22,594)	(13,593)
Accounts payable	30,413	(10,374)
Accrued liabilities	(38,070)	(8,317)
Income taxes, including excess tax benefits and deferred income taxes	(63,047)	(1,874)
Net cash provided by operating activities	(60,418)	184,917
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of property and equipment	(68,715)	(46,464)
Proceeds from sale of asset	933	218
Intangible assets additions	(6,560)	(10,216)
Payments to Acquire Equity Method Investments	0	(3,250)
Purchases of investment securities	(3,397)	(10,034)
Proceeds from sale of investment securities	36,433	12,000
Net cash used in investing activities	(1,885,470)	(57,746)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of long-term debt, net of lender debt issuance costs	1,672,631	0
Repayments of Long-term Debt	20,250	0
Payments of Debt Issuance Costs	(1,852)	0
Proceeds from exercise of stock options	7,906	6,966
Finance Lease, Principal Payments	(477)	(448)
Payment, Tax Withholding, Share-based Payment Arrangement	10,541	8,109
Net cash (used in) provided by financing activities	1,647,417	(1,591)
Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations	(10,477)	(2,192)
Effect of Exchange Rate on Cash [Abstract]
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect	(308,948)	123,388
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents	243,879	519,485
Supplemental Cash Flow Information [Abstract]
Capital Expenditures Incurred but Not yet Paid	2,757	2,897
NON-CASH INVESTING ACTIVITIES
Fair Value of Assets Acquired	1,658,937
Payments to Acquire Businesses, Net of Cash Acquired	(1,844,164)	0
Business Combination, Consideration Transferred, Equity Interests Issued and Issuable	(575,975)
Contingent consideration all Acquisitions	(55,158)
Goodwill, acquired during period	1,442,849
Liabilities Assumed	(626,489)
Foreign Infusion System Supplier
NON-CASH INVESTING ACTIVITIES
Liabilities Assumed	$ 0	$ (3,100)

Basis of Presentation_

Basis of Presentation:	9 Months Ended
	Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation [Text Block]	Basis of Presentation The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S.") and pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) and reflect all adjustments, consisting of only normal recurring adjustments, which are, in the opinion of management, necessary for a fair statement of the consolidated results for the interim periods presented. Results for the interim period are not necessarily indicative of results for the full year. Certain information and footnote disclosures normally included in annual consolidated financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted pursuant to such rules and regulations. The condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto included in the Annual Report on Form 10-K of ICU Medical, Inc., ("ICU"), a Delaware corporation, filed with the SEC for the year ended December 31, 2021. Certain reclassifications have been made to the prior year footnote information for revenue disaggregated by geography in Note 5: Revenues to conform to classifications used in the current year. These reclassifications had no impact on net loss, shareholder's equity or cash flows as previously reported. We are engaged in the development, manufacturing and sale of innovative medical products used in infusion therapy and critical care applications. We sell the majority of our products through our direct sales force and through independent distributors throughout the U.S. and internationally. We also sell certain products on an original equipment manufacturer basis to other medical device manufacturers. All subsidiaries are wholly owned and are included in the condensed consolidated financial statements. All intercompany balances and transactions have been eliminated. On January 6, 2022, we acquired Smiths Medical 2020 Limited ("Smiths Medical"), see Note 3: Acquisitions. Our condensed consolidated statement of operations includes the results of operations for Smiths Medical from January 7, 2022 through September 30, 2022. During the third quarter ended September 30, 2022, Smiths Medical changed their reporting period to align with ICU's calendar quarter from their historic 4-4-5 reporting period, this change did not have a material impact on our consolidated financial statements for the three and nine months ended September 30, 2022. Our condensed consolidated statement of operations includes the results of operations for Smiths Medical from June 26, 2022 through September 30, 2022 and January 7, 2022 through September 30, 2022 for the three and nine months ended September 30, 2022, respectively.

New Accounting Pronouncements_

New Accounting Pronouncements:	9 Months Ended
	Sep. 30, 2022
Accounting Standards Update and Change in Accounting Principle [Abstract]
New Accounting Pronouncements and Changes in Accounting Principles [Text Block]	New Accounting Pronouncements Recently Issued Accounting Standards In March 2020, the Financial Accounting Standards Board issued ASU No. 2020-04, Reference Rate Reform (Topic 848) - Facilitation of the Effects of Reference Rate Reform on Financial Reporting. The amendments in this update provide optional guidance for a limited period of time to ease the potential burden for reference rate reform on financial reporting. Due to concerns about structural risks of interbank offered rates and, particularly, the risk of cessation of the London Interbank Offered Rate ("LIBOR"), regulators around the world have undertaken reference rate reform initiatives to identify alternative reference rates that are more observable or transaction-based and less susceptible to manipulation. The amendments in this update apply only to contracts, hedging relationships, and other transactions that reference LIBOR or another reference rate expected to be discontinued as a result of reference rate reform. Optional expedients may be applied to contracts that are modified as a result of the reference rate reform. Modifications of contracts within the scope of Topic 470, Debt, should be accounted for by prospectively adjusting the effective interest rate. Modifications of contracts within the scope of ASC 842, Leases, should be accounted for as a continuation of the existing contracts with no reassessments of the lease classification and the discount rate (incremental borrowing rate). Exceptions to Topic 815, Derivatives and Hedging, results in not having a dedesignation of a hedging relationship if certain criteria are met. The amendments in this ASU are effective for all entities as of March 12, 2020 through December 31, 2022. In November 2021, we entered into two forward-starting swaps whereby the variable leg of the swap referenced LIBOR. These swaps were amended in early 2022 to transition to an alternative reference rate (see Note 8: Derivatives and Hedging Activities). The amendments in this ASU allow for certain expedients that will allow us to assume that our hedged interest payments are probable of occurring regardless of any expected modification in their terms related to reference rate reform and will allow us to continue hedge accounting for a cash flow hedge for which the hedged interest rate risk changes if the hedge is highly effective under ASC 815, Derivatives and Hedging, or the optional expedient under this ASU is elected. The impact of this ASU on our contracts has not been and is not expected to be material.

Business Combinations and Asset

Business Combinations and Asset Acquisitions	3 Months Ended
	Sep. 30, 2022
Business Combination and Asset Acquisition [Abstract]
Business Combination Disclosure	Acquisitions 2022 Acquisition On January 6, 2022, we acquired 100.0% of the equity interests in Smiths Medical, the holding company of Smiths Group plc's global medical device business, from Smiths Group International Holdings Limited (“Smiths”). The acquisition of Smiths Medical aligns with our strategic growth plans, enabling us to broaden our product offerings to include syringe and ambulatory infusion devices, vascular access, and vital care products and to strengthen and expand our global market reach. Total cash consideration for the acquisition was $1.9 billion, which was financed with existing cash balances and proceeds from the credit agreement entered into on January 6, 2022 (see Note 17: Long-Term Debt). We also issued share consideration to Smiths of 2.5 million shares of our common stock. The fair value of the common shares issued to Smiths was determined based on the opening market price of our common stock on the acquisition date. Smiths may be entitled to an additional $100.0 million in cash consideration contingent on our common stock achieving certain price targets for certain periods after closing in accordance with the terms of the Share Sale and Purchase Agreement (the "Purchase Agreement"). In the event that (a) on or prior to the third anniversary of closing the 30-day volume-weighted average price for our common stock, as defined in the Purchase Agreement, equals or exceeds $300.00 per share or (b) on or prior to the fourth anniversary of closing the 45-day volume-weighted average price for our common stock, as defined in the Purchase Agreement, equals or exceeds $300.00 per share (each a "Price Target"), and provided Smiths beneficially owns at least 50.0% of the shares of common stock issued at closing at the time the Price Target is achieved, then Smiths will be entitled to receive the additional $100.0 million in cash consideration. The fair value of the contingent consideration was determined using an option pricing model, specifically the Monte Carlo Simulation. In the analysis, the determinants of payout are simulated in a risk neutral framework over a large number of simulation paths. The fair value of the contingent consideration is then calculated as the average present value across all simulated paths. Preliminary Purchase Price Allocation The following table summarizes the estimated purchase price and the preliminary allocation of the purchase price related to the assets acquired and liabilities assumed (in thousands): Estimated cash consideration for acquired assets $ 1,922,955 Preliminary fair value of contingent consideration payable to Smiths 53,520 Issuance of ICU Medical, Inc. common shares: Number of shares issued to Smiths 2,500 Price per share (ICU's opening market price on the acquisition date) $ 230.39 Fair value of ICU shares issued to Smiths $ 575,975 Total estimated consideration to be paid $ 2,552,450 Preliminary Purchase Price Allocation: Cash and cash equivalents $ 78,791 Accounts receivable 118,522 Inventories 226,196 Prepaid expenses and other current assets 53,554 Property, plant and equipment 210,000 Operating lease right-of-use assets 55,161 Intangible assets (1) 975,000 Deferred income taxes 9,303 Other assets 379 Accounts payable (105,291) Accrued liabilities (2) (173,901) Income tax payable (24,332) Other long-term liabilities (85,739) Deferred income taxes (235,170) Total identifiable net assets acquired $ 1,102,473 Goodwill - not tax deductible 1,449,977 Estimated Purchase Consideration $ 2,552,450 _______________________________ (1) Estimated identifiable intangible assets include $540.0 million of customer relationships, $400.0 million of developed technology, $30.0 million of internally developed software, and $5.0 million of trademark. The estimated weighted-average amortization period for the total identifiable intangible assets is approximately nine eight ten five six (2) Estimated accrued liabilities includes, among other things, accrued warranty reserves, accrued restructuring initiatives, accrued salaries and related benefits, deferred revenue and accrued sales and use taxes. The above purchase price and purchase price allocation are preliminary and subject to future revision as the acquired assets and liabilities assumed are dependent upon the finalization of the related valuations. The identifiable intangible assets and other long-lived assets acquired have been valued as Level 3 assets at fair value. The estimated fair value of identifiable intangible assets were developed using the income approach and are based on critical estimates, judgments and assumptions derived from: analysis of market conditions; discount rate; discounted cash flows; royalty rates; customer retention rates; and/or estimated useful lives. Certain other intangible assets were valued using a cost to replace method, estimating the labor and non-labor costs required to replace the asset under the premise that it was not part of the transaction. Property, plant and equipment was valued with the consideration of remaining economic lives. The raw materials inventory was valued at historical cost and adjusted for any obsolescence which we estimate to approximate replacement cost, the work in process was valued at estimated sales proceeds less costs to complete and costs to sell, and finished goods inventory was valued at estimated sales proceeds less costs to sell. The prepaid expenses and other current assets and assumed liabilities were recorded at their carrying values as of the date of the acquisition, as their carrying values approximated their fair values due to their short-term nature. Unaudited Pro Forma Information Smiths Medical is included in our consolidated results beginning on January 7, 2022. Total revenues and net loss attributable to Smiths Medical for the period from January 7, 2022 to September 30, 2022 were estimated to be $699.1 million and $79.0 million, respectively, and for the three months ended September 30, 2022 were estimated to be $261.4 million and $13.6 million. The following unaudited pro forma financial information presents the combined results of operations of ICU and Smiths Medical as if the acquisition had occurred on January 1, 2021. The pro forma financial information is presented for informational purposes only and is not indicative of the results of operations that would have been achieved if the acquisition had taken place on the date indicated or of results that may occur in the future. Three months ended September 30, Nine months ended September 30, (In thousands) 2022 2021 2022 2021 Revenues $ 597,857 $ 641,115 $ 1,722,357 $ 1,862,237 Net Loss $ (13,208) $ (8,874) $ (54,840) $ 22,026 The unaudited pro forma results presented above include the impact of the following adjustments: incremental amortization expense on intangible assets acquired of $1.9 million and $1.9 million for the nine months ended September 30, 2022 and 2021, respectively, incremental interest expense, including amortization of debt discount and debt issuance costs, on the Senior Secured Credit Facilities (as defined in Note 17: Long-Term Debt) of $1.4 million and $47.1 million for the nine months ended September 30, 2022 and 2021, respectively; and a $27.4 million expense adjustment related to the increase in fair value of inventory to remove the expense for the nine months ended September 30, 2022 and to add the expense for the nine months ended September 30, 2021. In addition, there was a non-recurring adjustment directly attributable to the business combination for acquisition-related costs of $11.6 million for the nine months ended September 30, 2021. The unaudited pro forma results include IFRS to U.S. GAAP adjustments for Smiths Medical historical results and adjustments for accounting policy alignment, which were materially similar to the Company. Any differences in accounting policies were adjusted to reflect the accounting policies of the Company in the unaudited pro forma results presented. 2021 Acquisition

Restructuring, Strategic Transa

Restructuring, Strategic Transaction and Integration (Notes)	9 Months Ended
	Sep. 30, 2022
Restructuring and Related Activities [Abstract]
Restructuring and Related Activities Disclosure	Restructuring, Strategic Transaction and Integration Restructuring, strategic transaction and integration expenses were $14.4 million and $2.4 million for the three months ended September 30, 2022 and 2021, respectively, and $61.8 million and $9.0 million for nine months ended September 30, 2022 and 2021, respectively. Restructuring During the three and nine months ended September 30, 2022, restructuring charges were $2.4 million and $7.3 million, respectively, and were related to severance costs. During the third quarter 2021 we adjusted certain facility restructuring liabilities by $2.0 million to reflect actual amounts owed which resulted in net restructuring credits of $(1.9) million and $(1.8) million for the three and nine months ended September 30, 2021, respectively. The following table summarizes the activity in our restructuring-related accrual by major type of cost for the period ended September 30, 2022 (in thousands): Severance Pay and Benefits Retention and Facility Closure Costs Total Accrued balance, January 1, 2022 $ 499 $ 165 $ 664 Acquired restructuring liabilities 5,796 1,740 7,536 Charges incurred 3,222 — 3,222 Payments (2,030) — (2,030) Currency translation (147) (40) (187) Accrued balance, March 31, 2022 $ 7,340 $ 1,865 $ 9,205 Charges incurred 1,710 — 1,710 Payments (3,352) (212) (3,564) Currency translation (256) (94) (350) Other adjustments (38) — (38) Accrued balance, June 30, 2022 $ 5,404 $ 1,559 $ 6,963 Charges incurred 2,428 — 2,428 Payments (2,181) (19) (2,200) Currency translation (310) (114) (424) Accrued balance, September 30, 2022 $ 5,341 $ 1,426 $ 6,767 Strategic Transaction and Integration Expenses

Revenue (Notes)

Revenue (Notes)	9 Months Ended
	Sep. 30, 2022
Revenue from Contract with Customer [Abstract]
Revenue from Contract with Customer [Text Block]	RevenueRevenue Recognition Following our acquisition of Smiths Medical, our primary product lines are Infusion Consumables, Infusion Systems, IV Solutions, Critical Care, Infusion Systems-Smiths Medical, Vascular Access-Smiths Medical and Vital Care-Smiths Medical. The vast majority of our sales of these products are made on a stand-alone basis to hospitals and distributors. Revenue is typically recognized upon transfer of control of the products, which we deem to be at point of shipment. However, for purposes of revenue recognition for our software licenses and renewals, we consider the control of these products to be transferred to a customer at a certain point in time; therefore, we recognize revenue at the start of the applicable license term. Payment is typically due in full within 30 days of delivery or the start of the contract term. Revenue is recorded in an amount that reflects the consideration we expect to be entitled to in exchange for those goods or services. We offer certain volume-based rebates to our distribution customers, which we record as variable consideration when calculating the transaction price. Rebates are offered on both a fixed and tiered/variable basis. In both cases, we use information available at the time and our historical experience with each customer to estimate the most likely rebate amount. We also provide chargebacks to distributors that sell to end customers at prices determined under a contract between us and the end customer. Chargebacks are the difference between the prices we charge our distribution customers and the contracted prices we have with the end customer which are processed as credits to our distribution customers. In estimating the expected value of chargeback amounts in order to determine the transaction price, we use information available at the time, including our historical experience. We also warranty products against defects and have a policy permitting the return of defective products, for which we accrue and expense at the time of sale using information available at that time and our historical experience. We also provide for extended service-type warranties, which we consider to be separate performance obligations. We allocate a portion of the transaction price to the extended service-type warranty based on its estimated relative selling price, and recognize revenue over the period the warranty service is provided. Our revenues are recorded at the net sales price, which includes an estimate for variable consideration related to rebates, chargebacks and product returns. Revenue disaggregated The following table represents our revenues disaggregated by product line (in thousands): Three months ended Nine months ended Product line 2022 2021 2022 2021 Infusion Consumables $ 141,073 $ 144,850 $ 426,050 $ 407,419 Infusion Systems 87,846 90,688 262,111 259,683 IV Solutions 96,366 89,237 278,959 271,834 Critical Care 10,877 11,285 35,407 36,847 Infusion Systems-Smiths Medical 96,890 — 240,992 — Vascular Access-Smiths Medical 95,284 — 251,350 — Vital Care-Smiths Medical 69,521 — 207,114 — Total Revenues $ 597,857 $ 336,060 $ 1,701,983 $ 975,783 Infusion Systems-Smiths Medical, Vascular Access-Smiths Medical and Vital Care-Smiths Medical represent our newly integrated product lines following our acquisition of Smiths Medical on January 6, 2022. The following table represents our revenues disaggregated by geography (in thousands): Three months ended Nine months ended Geography 2022 2021 2022 2021 United States $ 376,691 $ 245,298 $ 1,088,348 $ 697,316 Canada 29,129 19,026 86,473 61,560 LATAM 23,599 14,875 59,827 44,191 Americas 429,419 279,199 1,234,648 803,067 Europe, the Middle East and Africa 101,869 36,239 275,488 108,800 APAC 66,569 20,622 191,847 63,916 Total Revenues $ 597,857 $ 336,060 $ 1,701,983 $ 975,783 Contract balances The following table presents the changes in our contract balances for the nine months ended September 30, 2022 and 2021 (in thousands): Contract Liabilities Beginning balance, January 1, 2022 $ (7,461) Fair value of acquired deferred revenue (51,245) Equipment revenue recognized 22,757 Equipment revenue deferred due to implementation (13,420) Software revenue recognized 12,761 Software revenue deferred due to implementation (12,978) Government grant deferred revenue (3,434) Government grant recognized 178 Other deferred revenue (1,285) Other deferred revenue recognized 3,488 Ending balance, September 30, 2022 $ (50,639) Beginning balance, January 1, 2021 $ (6,430) Equipment revenue recognized 7,193 Equipment revenue deferred due to implementation (8,652) Software revenue recognized 6,194 Software revenue deferred due to implementation (2,967) Ending balance, September 30, 2021 $ (4,662) As of September 30, 2022, revenue from remaining performance obligations is as follows: Recognition Timing (in millions) < 12 Months > 12 Months Equipment revenue $ (17,514) $ (621) Software revenue (8,248) (566) Government grant revenue (1,524) (13,735) Other revenue* (1,490) (6,941) Total $ (28,776) $ (21,863) _________________________________ *Other deferred revenue includes pump development programs, purchased training and extended warranty.

Leases (Notes)

Leases (Notes)	9 Months Ended
	Sep. 30, 2022
Leases [Abstract]
Lessee, Operating Leases [Text Block]	Leases We determine if an arrangement is a lease at inception. Our operating lease assets are separately stated in operating lease right-of-use ("ROU") assets and our financing lease assets are included in other assets on our condensed consolidated balance sheets. Our lease liabilities are included in accrued liabilities and other long-term liabilities on our condensed consolidated balance sheets. We have elected not to recognize an ROU asset and lease liability for leases with terms of twelve months or less. Lease ROU assets and lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. Most of our leases do not provide an implicit rate, therefore we use our incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term based on the information available at commencement date. Our lease ROU assets exclude lease incentives and initial direct costs incurred. Our lease terms include options to extend when it is reasonably certain that we will exercise that option. All of our leases have stated lease payments, which may include fixed rental increases. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. Our leases are for corporate, research and development and sales and support offices, distribution facilities, device service centers and certain equipment. Our leases have original lease terms of one year to fifteen years, some of which include options to extend the leases for up to an additional five years. For all of our leases, we do not include optional periods of extension in our current lease terms for the exercise of options to extend is not reasonably certain. The following table presents the components of our lease cost (in thousands): Three months ended Nine months ended 2022 2021 2022 2021 Operating lease cost $ 5,819 $ 2,798 $ 16,472 $ 8,455 Finance lease cost — interest 25 29 82 92 Finance lease cost — reduction of ROU asset 176 166 516 478 Short-term lease cost 1 4 7 14 Total lease cost $ 6,021 $ 2,997 $ 17,077 $ 9,039 Interest expense on our finance leases is included in other income (expense), net in our condensed consolidated statements of operations. The reduction of the operating and finance ROU assets is included as noncash lease expense in selling, general and administrative expenses in our condensed consolidated statements of operations. The following table presents the supplemental cash flow information related to our leases (in thousands): Nine months ended 2022 2021 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 18,886 $ 8,461 Operating cash flows from finance leases $ 25 $ 29 Right-of-use assets obtained in exchange for lease obligations: Operating leases $ 4,771 $ 1,394 Finance leases $ 266 $ 373 The following table presents the supplemental balance sheet information related to our operating leases (in thousands, except lease term and discount rate): As of September 30, 2022 December 31, 2021 Operating leases Operating lease right-of-use assets $ 76,438 $ 39,847 Accrued liabilities $ 18,638 $ 9,009 Other long-term liabilities 62,902 33,971 Total operating lease liabilities $ 81,540 $ 42,980 Weighted-Average Remaining Lease Term Operating leases 6.1 years 5.9 years Weighted-Average Discount Rate Operating leases 4.38 % 4.98 % The following table presents the supplemental balance sheet information related to our finance leases (in thousands, except lease term and discount rate): As of September 30, 2022 December 31, 2021 Finance leases Finance lease right-of-use assets $ 2,327 $ 2,673 Accrued liabilities $ 700 $ 643 Other long-term liabilities 1,692 2,067 Total finance lease liabilities $ 2,392 $ 2,710 Weighted-Average Remaining Lease Term Finance leases 4.9 years 5.6 years Weighted-Average Discount Rate Finance leases 4.26 % 4.28 % As of September 30, 2022, the maturities of our operating and finance lease liabilities for each of the next five years are approximately (in thousands): Operating Leases Finance Leases Remainder of 2022 $ 6,129 $ 197 2023 20,915 790 2024 17,157 524 2025 12,233 317 2026 10,980 217 2027 7,638 189 Thereafter 16,600 426 Total Lease Payments 91,652 2,660 Less imputed interest (10,112) (268) Total $ 81,540 $ 2,392

Net Income Per Share_

Net Income Per Share:	9 Months Ended
	Sep. 30, 2022
Earnings Per Share [Abstract]
Net Income Per Share [Text Block]	Net Income Per Share Basic earnings per share is computed by dividing net income by the weighted-average number of common shares outstanding during the period. Diluted earnings per share is computed by dividing net income by the weighted-average number of common shares outstanding during the period plus dilutive securities. Dilutive securities include outstanding common stock options and unvested restricted stock units, less the number of shares that could have been purchased with the proceeds from the exercise of the options, using the treasury stock method. Options and restricted stock units that are anti-dilutive are not included in the treasury stock method calculation. Due to the net loss for the three and nine months ended September 30, 2022, any potentially dilutive common shares were not included in the computation of diluted earnings per share as they would have had an anti-dilutive effect, therefore basic and diluted net loss per share are equal for the period. There were 12,235 and 12,132 anti-dilutive securities for the three and nine months ended September 30, 2021, respectively. The following table presents the calculation of net earnings per common share (“EPS”) — basic and diluted (in thousands, except per share data): Three months ended Nine months ended 2022 2021 2022 2021 Net (loss) income $ (13,208) $ 31,081 $ (58,750) $ 83,210 Weighted-average number of common shares outstanding (basic) 23,908 21,214 23,828 21,189 Dilutive securities (1) — 516 — 546 Weighted-average common and common equivalent shares outstanding (diluted) 23,908 21,730 23,828 21,735 EPS — basic $ (0.55) $ 1.47 $ (2.47) $ 3.93 EPS — diluted $ (0.55) $ 1.43 $ (2.47) $ 3.83 _______________________________ (1) No dilutive effect for the three and nine months ended September 30, 2022; therefore, zero incremental shares included for the period.

Derivative Financial Instrument

Derivative Financial Instruments (Notes)	3 Months Ended
	Sep. 30, 2022
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Instruments and Hedging Activities Disclosure [Text Block]	Derivatives and Hedging Activities Hedge Accounting and Hedging Program The purposes of our cash flow hedging programs are to manage the foreign currency exchange rate risk on forecasted revenues and expenses denominated in currencies other than the functional currency of the operating unit, and to manage floating interest rate risk associated with future interest payments on the variable-rate term loans issued in January 2022. We do not issue derivatives for trading or speculative purposes. To receive hedge accounting treatment, all hedging relationships are formally documented at the inception of the hedge, and the hedges must be highly effective in offsetting changes to future cash flows on hedged transactions. The derivative instruments we utilize, including various foreign exchange contracts and interest rate swaps, are designated and qualify as cash flow hedges. Our derivative instruments are recorded at fair value on the condensed consolidated balance sheets and are classified based on the instrument's maturity date. We record gains or losses from changes in the fair values of the derivative instruments as a component of other comprehensive income (loss) and we reclassify those gains or losses into earnings in the same line item associated with the forecasted transaction and in the same period during which the hedged transaction affects earnings. If the underlying forecasted transaction does not occur, or it becomes probable that it will not occur, we reclassify the gain or loss on the related derivative instrument from accumulated other comprehensive loss into earnings immediately. Foreign Currency Exchange Rate Risk Foreign Exchange Forward Contracts We enter into foreign exchange forward contracts to hedge a portion of our forecasted foreign currency-denominated revenues and expenses to minimize the effect of foreign exchange rate movements on the related cash flows. These contracts are agreements to buy or sell a quantity of a currency at a predetermined future date and at a predetermined exchange rate. Our foreign exchange forward contracts hedge exposures principally denominated in Mexican Pesos ("MXN"), Euros, Czech Koruna ("CZK"), Japanese Yen ("JPY"), U.S. Dollar ("USD"), Chinese Renminbi ("CNH"), Canadian Dollar ("CAD") and Australian Dollar ("AUD") and have varying maturities with an average term of approximately twelve months. The total notional amount of these outstanding derivative contracts as of September 30, 2022 was $145.2 million, which included the notional equivalent of $31.5 million in MXN, $27.9 million in Euros, $10.9 million in CZK, $12.2 million in JPY, $15.0 million in CNH, $26.2 million in USD, $11.7 million in CAD, $6.8 million in AUD and $3.1 million in other foreign currencies, with terms currently through July 2023. We did not have such derivative contracts as of December 31, 2021. Cross-currency Par Forward Contracts We enter into cross-currency par forward contracts to hedge a portion of our Mexico forecasted expenses denominated in MXN. These contracts are agreements to exchange cash flows from one currency to another at specified intervals over the contract term with all exchanges occurring at the same predetermined rate. In November 2021, we entered into a one-year cross-currency par forward contract with a term from December 1, 2021 to December 1, 2022. The total notional amount of this outstanding derivative as of September 30, 2022 and December 31, 2021 was approximately 103.8 million MXN and 413.1 million MXN, respectively. The derivative instrument matures in equal monthly amounts at a fixed forward rate of 21.60 MXN/USD. Preceding this contract we had a one-year cross-currency par forward contract with a term from November 3, 2020 to December 1, 2021 that matured in equal monthly amounts at a fixed forward rate of 24.26 MXN/USD. Floating Interest Rate Risk In November 2021, in anticipation of entering into the new senior secured credit facilities in January 2022, which includes a variable-rate term loan A and a variable-rate term loan B (see Note 17: Long-Term Debt), we entered into two forward-starting interest rate swaps. In February 2022, certain terms under the agreements were amended to reflect the transition from LIBOR to the Secured Overnight Financing Rate ("SOFR"), an alternative reference rate. Under the interest rate swap agreements we exchange, at specified intervals, the difference between fixed and floating interest amounts calculated by reference to an agreed-upon notional amount. Effective March 30, 2022, the term loan A swap, as amended, has an initial notional amount of $300.0 million, reducing to $150.0 million evenly on a quarterly basis excluding its final maturity on March 30, 2027. We will pay a fixed rate of 1.32% and will receive the greater of 3-month USD SOFR or (0.15)%. Effective March 30, 2022, the term loan B swap, as amended, has an initial notional amount of $750.0 million, reducing to $46.9 million evenly on a quarterly basis excluding its final maturity on March 30, 2026. We will pay a fixed rate of 1.17% and will receive the greater of 3-month USD SOFR or 0.35%. These swaps effectively convert the relevant portion of the floating-rate term loans to fixed rates. The following table presents the fair values of our derivative instruments included within the Condensed Consolidated Balance Sheets (in thousands): Derivatives Designated as Cash Flow Hedging Instruments Condensed Consolidated Balance Sheet Location Foreign Exchange Contracts Interest Rate Swaps Gross Derivatives As of September 30, 2022 Prepaid expenses and other current assets $ 11,695 $ 24,924 $ 36,619 Other assets — 33,386 33,386 Total assets $ 11,695 $ 58,310 $ 70,005 Accrued liabilities $ 1,752 $ — $ 1,752 Other long-term liabilities — — — Total liabilities $ 1,752 $ — $ 1,752 As of December 31, 2021 Prepaid expenses and other current assets $ 1,061 $ — $ 1,061 Other assets — — — Total assets $ 1,061 $ — $ 1,061 Accrued liabilities $ — $ — $ — Other long-term liabilities — 1,480 1,480 Total liabilities $ — $ 1,480 $ 1,480 We recognized the following gains on our derivative instruments designated as cash flow hedges (in thousands): Gain (Loss) Recognized in Other Comprehensive Income Three months ended Nine months ended 2022 2021 2022 2021 Derivatives designated as cash flow hedging instruments: Foreign exchange contracts $ 3,383 $ (109) $ 11,720 $ (70) Interest rate swaps 21,201 — 60,398 — Total derivatives designated as cash flow hedging instruments $ 24,584 $ (109) $ 72,118 $ (70) The following table presents the effects of our derivative instruments designated as cash flow hedges on the Condensed Consolidated Statements of Operations (in thousands): Gain (Loss) Reclassified From Accumulated Other Comprehensive (Loss) Income into Income Three months ended Nine months ended Location of Gain (Loss) Recognized in Income 2022 2021 2022 2021 Derivatives designated as cash flow hedging instruments: Foreign exchange contracts Total revenues $ (1,690) $ — $ 2,666 $ — Foreign exchange contracts Cost of goods sold 3,090 968 4,140 2,713 Foreign exchange contracts Interest expense (1) 462 — 717 — Interest rate swaps Interest expense 2,133 — 608 — Total derivatives designated as cash flow hedging instruments $ 3,995 $ 968 $ 8,131 $ 2,713 _______________________________ (1) Represents location of gain reclassified from accumulated other comprehensive income into income as a result of a forecasted transaction being no longer probable of occurring.

Fair Value Measures and Disclos

Fair Value Measures and Disclosures (Notes)	9 Months Ended
	Sep. 30, 2022
Fair Value Disclosures [Abstract]
Fair Value Disclosures	Fair Value Measurements Fair value is the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. There are three levels of inputs that may be used to measure fair value: • Level 1: quoted prices in active markets for identical assets or liabilities; • Level 2: inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities; or • Level 3: unobservable inputs that are supported by little or no market activity and that are significant to the fair values of the assets or liabilities. Contingent Earn-out Liabilities On January 6, 2022, we acquired Smiths Medical with a combination of cash consideration and share consideration issued at closing. Total consideration for the acquisition includes a potential earn-out payment of $100.0 million in cash contingent on our common stock achieving certain Price Targets from the closing date to either the third or fourth anniversary of closing (see Note 3: Acquisitions for additional information) and provided Smiths beneficially owns at least 50.0% of the shares of common stock issued at closing at the time the Price Target is achieved. The initial estimated fair value of the earn-out was determined to be $53.5 million. The initial fair value of the earn-out was determined using a Monte Carlo simulation model. The model utilized several assumptions including volatility and the risk-free interest rate. The assumed volatility is based on the average of the historical volatility of our common stock price and the implied volatility of certain at-the-money traded options. The risk-free interest rate is equal to the yield on U.S. Treasury securities at constant maturity for the period commensurate with the term of the earn-out. At each reporting date subsequent to the acquisition, we will remeasure the earn-out liability and recognize any changes in its fair value in our consolidated statements of operations. If the probability of achieving the Price Targets during their respective measurement periods is significantly greater than initially anticipated, the realization of an additional liability and related expense will have a significant impact on our consolidated financial statements in the period recognized. As of September 30, 2022, the estimated fair value of the contingent earn-out is $21.8 million. During November 2021, we acquired a small foreign infusion systems supplier. Total consideration for the acquisition includes a potential earn-out payment of up to $2.5 million, consisting of (i) a cash payment of $1.0 million contingent on the achievement of certain revenue targets for the annual period ending December 31, 2022 and, separately, (ii) a cash payment of $1.5 million contingent on certain product-related regulatory certifications obtained by May 26, 2024. As of September 30, 2022, the estimated fair value of the total contingent earn-out is $1.8 million. During August 2021, we entered into an agreement with one of our international distributors whereby that distributor would not compete with us in a specific territory for a three-year period that will end in September 2024. The terms of the agreement include a contingent earn-out payment. The contingent earn-out payment shall not exceed $6.0 million, which will be earned based on certain revenue targets over a twelve-month measurement period determined by the highest four consecutive quarters commencing over a two-year period starting on the closing date of the agreement and provided that the distributor is in compliance with its obligations under the agreement. As of both September 30, 2022 and December 31, 2021, the estimated fair value of the contingent earn-out is $2.6 million. The estimated fair value of the contingent earn-out is calculated using a probability-weighted cash flow model based on historical revenue streams and the likelihood that the revenue targets will be met. During the fourth quarter of 2019, we recognized an earn-out liability related to the acquisition of Pursuit Vascular, Inc. ("Pursuit"). Pursuit's former equity holders were entitled to up to $50.0 million in additional cash consideration contingent upon the achievement of certain sales and gross profit targets for specific customers. The earn-out was calculated as a percentage of gross profit achieved during the earn-out period against a pre-determined target gross profit, not to exceed $50.0 million. During the earn-out period, we used a Monte Carlo simulation model to determine the fair value of the earn-out liability. The Monte Carlo simulation model utilized multiple input variables to determine the value of the earn-out liability including historical volatility, a risk-free interest rate, counter party credit risk and projected future gross profit (see the simulation input table below related to Pursuit). The historical volatility was based on the median of ICU and a certain peer group. The risk-free interest rate was equal to the yield, as of the valuation date, of the zero-coupon U.S. Treasury bill that was commensurate with the term of the earn-out. The counter party credit risk was based on a synthetic credit rating of B1. As of June 30, 2021, the earn-out measurement period ended. Based on the actual sales and gross profit achieved during the measurement period, we calculated the actual earn-out amount to be $26.3 million. The $26.3 million earn-out calculation was finalized and accepted by Pursuit's former equity holders and was paid out in the fourth quarter of 2021. Our contingent earn-out liabilities are separately stated on our condensed consolidated balance sheets. The following tables provide a reconciliation of the Level 3 earn-out liabilities measured at estimated fair value (in thousands): Earn-out Liability Accrued balance, January 1, 2022 $ 2,589 Acquisition date fair value estimate of earn-out (1) 55,158 Currency translation (46) Accrued balance, March 31, 2022 $ 57,701 Change in fair value of earn-out (included in income from operations as a separate line item) (2) (27,194) Currency translation (98) Accrued balance, June 30, 2022 $ 30,409 Change in fair value of earn-out (included in income from operations as a separate line item) (2) (4,059) Currency translation (108) Accrued balance, September 30, 2022 $ 26,242 _______________________________ (1) $53.5 million relates to our acquisition of Smiths Medical and $1.6 million relates to our acquisition of a small foreign infusions systems supplier in the fourth quarter of 2021 (see Note 3: Acquisitions). (2) Primarily relates to the change in fair value of the Smiths Medical earn-out. Earn-out Liability Accrued balance, January 1, 2021 $ 26,300 Change in fair value of earn-out (included in income from operations as a separate line item) — Accrued balance, March 31, 2021 $ 26,300 Change in fair value of earn-out (included in income from operations as a separate line item) — Accrued balance, June 30, 2021 $ 26,300 Contingent earn-out — non-compete arrangement 3,100 Transfer of Pursuit earn-out liability into Level 2 (26,300) Accrued balance, September 30, 2021 $ 3,100 The following tables provide quantitative information about Level 3 inputs for fair value measurement of our earn-out liabilities related to Smiths Medical and Pursuit: Smiths Medical Earn-out Simulation Input As of At Acquisition Volatility 42.00 % 37.00 % Risk-Free Rate 4.18 % 1.31 % Pursuit Earn-out Simulation Input As of Revenue/Gross Profit Volatility 25.00 % Discount Rate 12.50 % Risk-Free Rate 0.09 % Counter Party Risk 3.10 % Investments, Foreign Exchange Contracts and Interest Rate Contracts Our investments consist of corporate bonds and U.S treasury securities. The fair value of our corporate bonds is estimated using observable market-based inputs such as quoted prices, interest rates and yield curves or Level 2 inputs. The fair value of our U.S. treasury securities are based on quoted market prices in active markets and are included in the Level 1 fair value hierarchy. The fair value of our Level 2 foreign exchange contracts, including forward contracts and cross-currency par forward contracts, is estimated using observable market inputs such as known notional value amounts, spot and forward exchange rates. These inputs relate to liquid, heavily traded currencies with active markets which are available for the full term of the derivative. The fair value of our Level 2 interest rate swaps is estimated using a pricing model that reflects the terms of the contracts, including the period to maturity, and relies on observable market inputs such as known notional value amounts and USD interest rate curves. Our assets and liabilities measured at fair value on a recurring basis consisted of the following Level 1, 2 and 3 inputs as defined above (in thousands): Fair value measurements as of September 30, 2022 Total carrying Quoted prices Significant Significant Assets: Available-for-sale debt securities: Short-term corporate bonds $ 1,511 $ — $ 1,511 $ — Short-term U.S. treasury securities 1,408 1,408 — — Long-term corporate bonds 1,333 — 1,333 — Long-term government bonds 498 — 498 — Foreign exchange contracts: Prepaid expenses and other current assets 11,695 — 11,695 — Other assets — — — — Interest rate contracts: Prepaid expenses and other current assets 24,924 — 24,924 — Other assets 33,386 — 33,386 — Total Assets $ 74,755 $ 1,408 $ 73,347 $ — Liabilities: Contingent earn-out liability - ST $ 300 $ — $ — $ 300 Contingent earn-out liability - LT 25,942 — — 25,942 Foreign exchange contracts: Accrued liabilities 1,752 — 1,752 — Total Liabilities $ 27,994 $ — $ 1,752 $ 26,242 Fair value measurements as of December 31, 2021 Total carrying Quoted prices Significant Significant Assets: Available-for-sale debt securities: Short-term corporate bonds $ 14,420 $ — $ 14,420 $ — Long-term corporate bonds 4,620 — 4,620 — Cross-currency par forward contract: Prepaid expenses and other current assets 1,061 — 1,061 — Total Assets $ 20,101 $ — $ 20,101 $ — Liabilities: Contingent earn-out liability - LT $ 2,589 $ — $ — $ 2,589 Forward-starting interest rate swaps: Other long-term liabilities 1,480 — 1,480 — Total Liabilities $ 4,069 $ — $ 1,480 $ 2,589

Investment Securities (Notes)

Investment Securities (Notes)	9 Months Ended
	Sep. 30, 2022
Investments, Debt and Equity Securities [Abstract]
investments in Debt and Marketable Equity Securities and Equity Method Investments [Text Block]	Investment Securities Investments in Available-for-sale Securities Our available-for-sale investment securities currently consist of short-term and long-term corporate bonds, short-term U.S. treasury securities and long-term government bonds and are considered “investment grade” and are carried at fair value. We assess our investment in available-for-sale debt securities for impairment each reporting period. If an unrealized loss exists, we determine whether any portion of the decline in fair value below the amortized cost basis is credit-related by reviewing several factors, including, but not limited to, the extent of the fair value decline and changes in the financial condition of the issuer. We record an impairment for credit-related losses through an allowance, limited to the amount of the unrealized loss. If we either intend to sell or it is more likely than not we will be required to sell the debt security before its anticipated recovery, any allowance is written off and the amortized cost basis is written down to fair value through a charge against net earnings. Unrealized gains and non-credit-related unrealized losses are recorded, net of tax, in other comprehensive income (loss). We did not have any investments in available-for-sale debt securities in unrealized loss positions as of September 30, 2022 or December 31, 2021. The amortized cost of the debt securities are adjusted for the amortization of premiums computed under the effective interest method. Such amortization is included in other income, net in our condensed consolidated statements of operations. Realized gains and losses are accounted for on the specific identification method. There have been no realized gains or losses on the disposal of these investments. The scheduled maturities of the debt securities are between 2022 and 2024. All short-term investment securities are callable within one year. Our short-term and long-term investments in available-for-sale securities consist of the following (in thousands): As of September 30, 2022 Amortized Cost Unrealized Holding Fair Value Short-term corporate bonds $ 1,511 $ — $ 1,511 Short-term U.S. treasury securities 1,408 — 1,408 Long-term corporate bonds 1,333 — 1,333 Long-term government bonds 498 — 498 Total investment securities $ 4,750 $ — $ 4,750 As of December 31, 2021 Amortized Cost Unrealized Holding Fair Value Short-term corporate bonds $ 14,420 $ — $ 14,420 Long-term corporate bonds 4,620 — 4,620 Total investment securities $ 19,040 $ — $ 19,040 Investments in Non-Marketable Equity Securities During the third quarter of 2021, we acquired approximately a 20.0% non-marketable equity interest in a nonpublic company and entered into a three-year distribution agreement where we have the exclusive rights to market, sell and distribute the company's products in exchange for a cash payment of $3.3 million. In addition, we were granted an exclusive license for all of the seller's intellectual property. At the expiration of the distribution agreement we have the right but not the obligation to acquire the remaining interest in the business. We apply the equity method of accounting for investments when we determine we have a significant influence, but not a controlling interest in the investee. We determine whether we have significant influence by considering key factors such as ownership interest, representation on the board of directors, participation in policy making decisions, business relationship and material intra-entity transactions, among other factors. Our equity method investment is reported at cost and adjusted each period for our share of the investee's income or (loss) and dividend paid, if any. We eliminate any intra-entity profits to the extent of our beneficial interest. We record our share of the investee's income or (loss) on a one quarter lag. We report our proportionate share of the investee's income or (loss) resulting from this investment in other income, net in our condensed consolidated statements of operations. The carrying value of our equity method investment is reported in other assets on our condensed consolidated balance sheets (see Note 11: Prepaid Expenses and Other Current Assets and Other Assets). We assess our equity method investments for impairment on an annual basis or whenever events or circumstances indicate that the carrying value of the investment may not be recoverable. Our recorded share of the investee's loss was not material for the three and nine months ended September 30, 2022. We did not receive any dividend distributions from this investment during the three and nine months ended September 30, 2022. Our non-marketable equity method investment consists of the following (in thousands): As of September 30, 2022 December 31, 2021 Equity method investment $ 3,188 $ 3,238 Investments in non-marketable debt securities During the second quarter 2022, we received $19.0 million in proceeds from a promissory note related to an acquired investment as part of the Smiths Medical acquisition.

Prepaids and Other Current Asse

Prepaids and Other Current Assets (Notes)	9 Months Ended
	Sep. 30, 2022
Prepaid Expense and Other Assets [Abstract]
Prepaids, other current assets and other noncurrent assets [Text Block]	Prepaid Expenses and Other Current Assets and Other Assets Prepaid expenses and other current assets consist of the following (in thousands): As of September 30, 2022 December 31, 2021 Other prepaid expenses and receivables $ 22,738 $ 14,763 Prepaid vendor expenses 2,641 — Deferred costs 3,775 12,746 Prepaid insurance and property taxes 14,019 6,310 VAT/GST receivable 2,946 4,156 Deferred tax charge 4,452 4,241 Foreign exchange contracts 11,695 1,061 Interest rate contracts 24,924 — Interest receivable 2,426 293 Deposits 1,312 1,343 Other 3,355 1,934 $ 94,283 $ 46,847 Other assets consist of the following (in thousands): As of September 30, 2022 December 31, 2021 Pump lease receivables $ 27,024 $ 25,941 Spare parts 36,937 28,538 Equity method investments 3,188 3,238 Deferred debt issuance costs 5,586 2,827 Finance lease right-of-use assets 2,327 2,673 Interest rate contracts 33,386 — Other 2,156 526 $ 110,604 $ 63,743

Inventories_

Inventories:	9 Months Ended
	Sep. 30, 2022
Inventory Disclosure [Abstract]
Inventories [Text Block]	Inventories Inventories are stated at the lower of cost or net realizable value with cost determined using the first-in, first-out method. Inventory costs include material, labor and overhead related to the manufacturing of our products. Inventories consist of the following (in thousands): As of September 30, 2022 December 31, 2021 Raw materials $ 264,518 $ 135,528 Work in process 71,367 36,490 Finished goods 289,383 118,217 Total inventories $ 625,268 $ 290,235 During 2022, inventories increased significantly due to the acquisition of Smiths Medical. All acquired inventory was recorded at fair value on January 6, 2022 in accordance with ASC 805, Business Combinations (see Note 3: Acquisitions).

Property and Equipment_

Property and Equipment:	9 Months Ended
	Sep. 30, 2022
Property, Plant and Equipment [Abstract]
Property and Equipment [Text Block]	Property, Plant and Equipment Property, plant and equipment consists of the following (in thousands): As of September 30, 2022 December 31, 2021 Machinery and equipment $ 409,349 $ 321,078 Land, building and building improvements 272,426 243,377 Molds 75,874 60,463 Computer equipment and software 114,378 102,979 Furniture and fixtures 29,110 7,670 Instruments placed with customers (1) 106,245 97,384 Construction in progress 147,099 72,153 Total property, plant and equipment, cost 1,154,481 905,104 Accumulated depreciation (498,098) (436,739) Property, plant and equipment, net $ 656,383 $ 468,365 ______________________________ (1) Instruments placed with customers consist of drug-delivery and monitoring systems placed with customers under operating leases. Depreciation expense was $23.0 million and $69.4 million for the three and nine months ended September 30, 2022, respectively. Depreciation expense was $16.4 million and $49.1 million for the three and nine months ended September 30, 2021, respectively. During the three and nine months ended September 30, 2022, property, plant and equipment and related depreciation expense increased significantly due to the acquisition of Smiths Medical (see Note 3: Acquisitions).

Goodwill and Intangible Assets

Goodwill and Intangible Assets (Notes)	9 Months Ended
	Sep. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets Disclosure [Text Block]	Goodwill and Intangible Assets, Net Goodwill The following table presents the changes in the carrying amount of our goodwill (in thousands): Total Balance as of January 1, 2022 $ 43,439 Goodwill acquired (1) 1,449,977 Other (2) (7,128) Currency translation (116,571) Balance as of September 30, 2022 $ 1,369,717 _______________________________ (1) Relates to Smiths Medical acquired on January 6, 2022. (2) Other reflects measurement period adjustments related to a 2021 acquisition of a small foreign infusion systems supplier. Intangible Assets, Net Intangible assets, carried at cost less accumulated amortization and amortized on a straight-lined basis, were as follows (in thousands): Weighted-Average Amortization Life in Years September 30, 2022 Cost Accumulated Net Patents 10 $ 29,301 $ 18,135 $ 11,166 Customer contracts 12 9,909 6,339 3,570 Non-contractual customer relationships 8 560,691 85,081 475,610 Trademarks 1 5,425 5,425 — Trade name 15 18,244 5,643 12,601 Developed technology 10 576,687 93,490 483,197 Non-compete 3 9,100 4,631 4,469 Total amortized intangible assets $ 1,209,357 $ 218,744 $ 990,613 Internally developed software* $ 30,045 $ 30,045 Total intangible assets $ 1,239,402 $ 218,744 $ 1,020,658 ______________________________ * Internally developed software will be amortized when the projects are complete and the assets are ready for their intended use. Weighted-Average Amortization Life in Years December 31, 2021 Cost Accumulated Net Patents 10 $ 27,429 $ 16,764 $ 10,665 Customer contracts 12 10,412 6,196 4,216 Non-contractual customer relationships 9 57,316 33,004 24,312 Trademarks 4 425 425 — Trade name 15 18,260 4,731 13,529 Developed technology 13 152,893 49,406 103,487 Non-compete 3 9,100 2,356 6,744 Total amortized intangible assets $ 275,835 $ 112,882 $ 162,953 Internally developed software* $ 25,358 $ 25,358 Total intangible assets $ 301,193 $ 112,882 $ 188,311 ______________________________ * Internally developed software will be amortized when the projects are complete and the assets are ready for their intended use. Intangible assets with definite lives are amortized on a straight-line basis over their estimated useful lives. During the three months ended September 30, 2022 and 2021, intangible asset amortization expense was $35.6 million and $5.8 million, respectively. During the nine months ended September 30, 2022 and 2021, intangible asset amortization expense was $108.9 million and $17.4 million, respectively. During the three and nine months ended September 30, 2022, intangible assets and related amortization expense increased significantly due to the acquisition of Smiths Medical (see Note 3: Acquisitions). As of September 30, 2022 estimated annual amortization for our intangible assets for each of the next five years is approximately (in thousands): Remainder of 2022 $ 33,624 2023 132,368 2024 131,729 2025 123,901 2026 123,502 2027 115,491 Thereafter 329,998 Total $ 990,613

Accrued Liabilities (Notes)

Accrued Liabilities (Notes)	9 Months Ended
	Sep. 30, 2022
Accrued Liabilities [Abstract]
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	Accrued Liabilities and Other Long-Term Liabilities Accrued liabilities consist of the following (in thousands): As of September 30, 2022 December 31, 2021 Salaries and benefits $ 49,409 $ 27,304 Incentive compensation 24,388 33,107 Operating lease liability-ST 18,638 9,009 Accrued sales taxes 6,507 1,980 Restructuring accrual 6,767 664 Deferred revenue 31,183 12,646 Accrued other taxes 4,415 4,337 Accrued professional fees 8,694 773 Legal accrual 4,240 3,897 Distribution fees 25,326 5,645 Warranties and returns 3,059 532 Field service corrective action (1) 24,857 — Accrued freight 14,234 9,194 Foreign exchange contracts 1,752 — Accrued audit fees 6,095 1,008 Defined benefit plan 2,527 — Accrued interest 2,788 — Other 9,424 8,099 $ 244,303 $ 118,195 ___________________________ (1) Relates to field corrective actions associated with certain products in connection with a 2021 Warning Letter received by Smiths Medical from the FDA following an inspection of Smiths Medical’s Oakdale, Minnesota Facility, see Note 19: Commitments and Contingencies for further detail. As of September 30, 2022 December 31, 2021 Operating lease liability-LT $ 62,902 $ 33,971 Benefits 5,958 1,369 Accrued rent 1,030 1,262 Forward-starting interest rate swaps — 1,480 Finance lease liability-LT 1,692 2,067 Deferred revenue 21,976 — Field service corrective action (1) 22,620 — Other 3,073 1,681 $ 119,251 $ 41,830

Income Taxes_

Income Taxes:	9 Months Ended
	Sep. 30, 2022
Income Tax Disclosure [Abstract]
Income Tax Disclosure [Text Block]	Income Taxes Income taxes were accrued at an estimated effective tax rate of 38% and 37% for the three and nine months ended September 30, 2022, respectively, as compared to 18% and 17% for the three and nine months ended September 30, 2021, respectively. The effective tax rate for the three and nine months ended September 30, 2022 differs from the federal statutory rate of 21% principally because of the effect of the mix of U.S. and foreign incomes, state income taxes, section 162(m) excess compensation, foreign-derived intangible income ("FDII") and tax credits and the following discrete items recognized during the interim period: • Excess tax benefits recognized on stock option exercises and the vesting of restricted stock units during the three and nine months ended September 30, 2022 of $1.5 million and $4.1 million, respectively. • The revaluation of the contingent consideration during the three and nine months ended September 30, 2022 of $4.1 million and $31.3 million, respectively, resulted in a tax expense of $0.0 million and $0.0 million, respectively. The effective tax rate for the three and nine months ended September 30, 2021 differs from the federal statutory rate of 21% principally because of the effect of the mix of U.S. and foreign incomes, state income taxes, global intangible low taxed income ("GILTI"), FDII and tax credits. The effective tax rate during the three and nine months ended September 30, 2021 included a discrete tax benefit of $1.1 million and $3.3 million, respectively, related to excess tax benefits recognized on stock option exercises and the vesting of restricted stock units during the period. Additionally, U.S. federal return-to-provision adjustments for the year ended December 31, 2020 primarily due to changes in estimates for GILTI, FDII, subpart F income, and related foreign tax credits along with other prior period adjustments resulted in a tax provision of $1.1 million for the three and nine months ended September 30, 2021.

Long-Term Obligations (Notes)

Long-Term Obligations (Notes)	9 Months Ended
	Sep. 30, 2022
LOng-Term Obligations Disclosure [Abstract]
Long-term Debt [Text Block]	Long-Term Debt 2022 Credit Agreement On January 6, 2022, in connection with the acquisition of Smiths Medical, we entered into a Credit Agreement (the "Credit Agreement") with Wells Fargo Bank, National Association, Wells Fargo Securities, LLC, Barclays Bank PLC and certain other financial institutions (the “Lenders”) for $2.2 billion of senior secured credit facilities. The senior secured credit facilities include (i) a five-year Tranche A term loan of $850.0 million (the "Term Loan A"), (ii) a seven-year Tranche B term loan of $850.0 million (the "Term Loan B") and (iii) a five-year revolving credit facility of $500.0 million (the "Revolving Credit Facility"), with separate sub-limits of $50.0 million for letters of credit and swingline loans (collectively, the "Senior Secured Credit Facilities"). We used the proceeds from borrowings under the Term Loan A and the Term Loan B (collectively, the "Term Loans") to fund a portion of the cash consideration for the purchase of Smiths Medical and the related fees and expenses incurred in connection with the acquisition. We did not incur borrowings under the Revolving Credit Facility on the closing date of the acquisition. The proceeds from any future borrowings under the Revolving Credit Facility may be used for working capital and other general corporate purposes. In connection with entering into the Credit Agreement, during the period ended March 31, 2022, we incurred $37.8 million in debt discount and issuance costs, which were allocated to the Term Loan A, the Term Loan B and the Revolving Credit Facility based on lender commitment amounts relative to each type of fees paid. The lender and third-party discount and issuance costs allocated to the Term Loan A and the Term Loan B were $15.8 million and $13.4 million, respectively, and are reflected as a direct deduction from the face amount of the corresponding term loans on the condensed consolidated balance sheet. These costs are being amortized to interest expense over the respective terms of the loans using the effective interest method. The issuance costs allocated to the Revolving Credit Facility were $8.7 million, which are capitalized and included in prepaid expenses and other current assets and other assets on our condensed consolidated balance sheets. These costs are being amortized to interest expense over the term of the Revolving Credit Facility using the straight-line method. The net funds received from the Term Loan A and the Term Loan B, after deducting debt issuance costs, were $834.2 million and $836.6 million, respectively. Maturity Dates The maturity date for the Term Loan A and the Revolving Credit Facility is January 6, 2027, and the maturity date for the Term Loan B is January 6, 2029. Pursuant to the terms and conditions of the Credit Agreement, the maturity dates of the Term Loans and the Revolving Credit Facility may be extended upon our request, subject to the consent of the Lenders. Interest Rate Terms In general, the Term Loans and borrowings under the Revolving Credit Facility denominated in U.S. dollars bear interest, at our option, on either: (1) the Base Rate, as defined below, plus the applicable margin, as indicated below ("Base Rate Loans") or (2) the Adjusted Term Secured Overnight Financing Rate ("Adjusted Term SOFR"), as defined below, plus the applicable margin, as indicated below ("Term SOFR Loans"). The Base Rate is defined as the highest of (a) the Prime Rate, (b) the Federal Funds Rate plus 0.50% and (c) Adjusted Term SOFR (as defined below) for a one-month period plus, in each case, 1.00%. Adjusted Term SOFR is the rate per annum equal to (a) the Term SOFR plus (b) the Term SOFR Adjustment. Term SOFR is the forward-looking term rate based on SOFR and is calculated separately for Term SOFR Loans and Base Rate Loans, as specified in the Credit Agreement. The Term SOFR Adjustment is a percentage per annum of 0.10% for Base Rate Loans and between 0.10% to 0.25% for Term SOFR Loans based on the applicable interest period. Revolving Credit Facility Commitment Fee The Revolving Credit Facility has a per annum commitment fee at an initial rate of 0.25% which is applied to the available amount of the Revolving Credit Facility. Effective on the first Adjustment Date, as defined in the Credit Agreement, occurring subsequent to our quarter ending June 30, 2022, the commitment fee will be determined by reference to the leverage ratio in effect from time to time as set forth in the table below. Applicable Interest Margins The Term Loan A and borrowings under the Revolving Credit Facility have an initial applicable margin of 0.75% per annum for Base Rate Loans and 1.75% per annum for Term SOFR Loans. Effective on the first Adjustment Date, as defined in the Credit Agreement, occurring subsequent to our quarter ending June 30, 2022, the applicable margin for the Term Loan A and borrowings under the Revolving Credit Facility will be determined by reference to the leverage ratio in effect from time to time as set forth in the following table: Leverage Ratio Applicable Margin for Term SOFR Loans Applicable Margin for Base Rate Loans Commitment Fee Rate Greater than 4.00 to 1.0 2.25% 1.25% 0.35% Less than or equal to 4.00 to 1.0 but greater than 3.00 to 1.0 2.00% 1.00% 0.30% Less than or equal to 3.00 to 1.0 but greater than 2.50 to 1.0 1.75% 0.75% 0.25% Less than or equal to 2.50 to 1.0 but greater than 2.00 to 1.0 1.50% 0.50% 0.20% Less than or equal to 2.00 to 1.0 1.25% 0.25% 0.15% The Term Loan B has an initial applicable margin of 1.5% per annum for Base Rate Loans and 2.5% per annum for Term SOFR Loans. Effective on the first Adjustment Date, as defined in the Credit Agreement, occurring subsequent to our quarter ending June 30, 2022, the applicable margin for the Term Loan B will be determined by reference to the leverage ratio in effect from time to time as set forth in the following table: Leverage Ratio Applicable Margin for Term SOFR Loans Applicable Margin for Base Rate Loans Greater than 2.75 to 1.0 2.50% 1.50% Less than 2.75 to 1.0 2.25% 1.25% Principal Payments Principal payments on the Term Loans are due on the last day of each calendar quarter commencing on June 30, 2022. The Term Loan A will amortize in nineteen consecutive quarterly installments in an amount equal to 2.50% of the original principal amount in each of the first two years, 5.00% in each of the third and fourth years and 7.50% in the fifth year, with a final payment of the remaining outstanding principal balance due on the maturity date. The Term Loan B matures in twenty-seven consecutive quarterly installments in an amount equal to 0.25% of the original principal amount, with a final payment of the remaining outstanding principal balance due on the maturity date. We may borrow, prepay and re-borrow amounts under the Revolving Credit Facility, in accordance with the terms and conditions of the Credit Agreement, with all outstanding amounts due at maturity. During March 2022, we prepaid $16.0 million in principal payments on the Term Loan A principal balance. For the nine months ended September 30, 2022, we paid total of $20.3 million in principal payments on both Term Loans. Interest Payments Interest payments on Base Rate Loans are payable quarterly in arrears on the last business day of each calendar quarter and the applicable maturity date. Interest periods on Term SOFR Loans will be determined, at our option, as either one, three or six months and will be payable on the last day of each interest period and the applicable maturity date. In the case of any interest periods of more than three months' duration, the interest payment will be payable on each day prior to the last day of such interest period that occurs at three-month intervals. The commitment fee on the Revolving Credit Facility is payable quarterly in arrears on the third business day following the last day of each calendar quarter and at the maturity date. The commitment fee is included in interest expense in our condensed consolidated statements of operations. Guarantors and Collateral Our obligations under the Credit Agreement are unconditionally guaranteed, on a joint and several basis, by ICU Medical, Inc. and certain of our existing subsidiaries. Debt Covenants The Credit Agreement contains affirmative and negative covenants, including certain financial covenants. The negative covenants include restrictions regarding the incurrence of liens and indebtedness, certain merger and acquisition transactions, asset sales and other dispositions, other investments, dividends, share purchases and payments affecting subsidiaries, changes in nature of business, fiscal year or organizational documents, prepayments and redemptions of subordinated and other junior debt, transactions with affiliates, and other matters. The financial covenants include the Senior Secured Leverage Ratio and the Interest Coverage Ratio, both defined below, and pertain to the Term Loan A and the Revolving Credit Facility. The Senior Secured Leverage Ratio is defined, at any measurement date, as the ratio of: (a) all Funded Debt, as defined in the Credit Agreement, that is secured by a lien on any asset or property minus the lesser of (i) all unrestricted cash and cash equivalents and (ii) $500.0 million, to (b) Consolidated EBITDA, as defined in the Credit Agreement, for the most recently completed four fiscal quarters, calculated on a pro forma basis. The maximum Senior Secured Leverage Ratio is 4.50 to 1.00 until June 30, 2024. Thereafter, the maximum Senior Secured Leverage Ratio is 4.00 to 1.00, with limited permitted exception. The Interest Coverage ratio is defined, at any measurement date, as the ratio of Consolidated EBITDA, as defined in the Credit Agreement, to Consolidated Interest Expense, as defined in the Credit Agreement, paid or payable in cash, for the most recently completed four fiscal quarters. The minimum Interest Coverage ratio is 3.00 to 1.00. We were in compliance with all financial covenants as of September 30, 2022. The Credit Agreement contains customary events of default, including, among others: non-payments of principal and interest; breach of representations and warranties; covenant defaults; cross-defaults and cross-acceleration to certain other material indebtedness; the existence of bankruptcy or insolvency proceedings; certain events under ERISA; material judgments; and a change of control. If an event of default occurs and is not cured within any applicable grace period or is not waived, the administrative agent and the Lenders are entitled to take various actions, including, without limitation, the acceleration of all amounts due and the termination of commitments under the Senior Secured Credit Facilities. 2017 Credit Facility On November 8, 2017, we entered into a five-year senior secured revolving credit facility with various lenders for $150.0 million, with Wells Fargo Bank, National Association as the administrative agent, swingline lender and issuing lender (the "Prior Credit Facility"). The Prior Credit Facility, which was set to mature on November 8, 2022, was terminated in connection with entering into the Credit Agreement on January 6, 2022. There were no borrowings outstanding under the Prior Credit Facility at that date or at December 31, 2021. The remaining unamortized deferred debt issuance costs related to the Prior Credit Facility were not material and were expensed in connection with its termination. See further details of the terms of the Prior Credit Facility in Note 11 in Part II, Item 8, of our 2021 Annual Report on Form 10-K. The carrying values of our long-term debt consist of the following (in thousands): Effective Interest Rate As of Senior Secured Credit Facilities: Term Loan A — principal 3.39 % $ 834,000 Term Loan B — principal 3.98 % 845,750 Revolving Credit Facility — principal — % — Less unamortized debt issuance costs (1) (25,526) Total carrying value of long-term debt 1,654,224 Less current portion of long-term debt 24,375 Long-term debt, net $ 1,629,849 _______________________________ (1) Comprised of $13.4 million and $12.2 million relating to the Term Loan A and the Term Loan B, respectively. As of September 30, 2022, the aggregate amount of principal repayments of our long-term debt (including any current portion) for each of the next five years is approximately (in thousands): Remainder of 2022 $ 2,125 2023 29,750 2024 51,000 2025 51,000 2026 72,250 2027 672,500 Thereafter 801,125 Total $ 1,679,750 The following table presents the total interest expense related to our long-term debt (in thousands): Three months ended Nine months ended 2022 2021 2022 2021 Contractual interest $ 19,228 $ — $ 41,868 $ — Amortization of debt issuance costs 1,758 72 5,200 216 Commitment fee — Revolving Credit Facility 334 58 994 171 Total long-term debt-related interest expense $ 21,320 $ 130 48,062 387

Commitments and Contingencies_

Commitments and Contingencies:	9 Months Ended
	Sep. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies [Text Block]	Commitments and Contingencies Legal Proceedings From time to time, we are involved in various legal proceedings, most of which are routine litigation, in the normal course of business. Our management does not believe that the resolution of the unsettled legal proceedings that we are involved with will have a material adverse impact on our financial position or results of operations. Off-Balance Sheet Arrangements In the normal course of business, we have agreed to indemnify our officers and directors to the maximum extent permitted under Delaware law and to indemnify customers as to certain intellectual property matters or other matters related to sales of our products. There is no maximum limit on the indemnification that may be required under these agreements. Although we can provide no assurances, we have never incurred, nor do we expect to incur, any material liability for indemnification. Contingencies On January 6, 2022, we acquired Smiths Medical. Total consideration for the acquisition includes a potential earn-out payment of $100.0 million in cash contingent on our common stock achieving a certain volume-weighted average price from the closing date to either the third or fourth anniversary of closing. As of September 30, 2022, the estimated fair value of the contingent earn-out is $21.8 million (see Note 9: Fair Value Measurements). Prior to being acquired, during 2021, Smiths Medical received a Warning Letter from the FDA following an inspection of Smiths Medical’s Oakdale, Minnesota Facility. The Warning Letter cited, among other things, failures to comply with FDA's medical device reporting requirements and failures to comply with applicable portions of the Quality System Regulation. A provision for the estimated costs related to the field service corrective action was recorded on the opening acquired balance sheet of Smiths Medical in the amount of $55.1 million. The initial estimate recorded was based on a probability-weighted estimate of the costs required to settle the obligation. The actual costs to be incurred are dependent upon the scope of the work necessary to achieve regulatory clearance and could differ from the original estimate. The estimated field service corrective action recorded at September 30, 2022 is $47.5 million. During November 2021, we acquired a small foreign infusion systems supplier. Total consideration for the acquisition includes a potential earn-out payment of up to $2.5 million, consisting of (i) a cash payment of $1.0 million contingent on the achievement of certain revenue targets for the annual period ending December 31, 2022 and, separately, (ii) a cash payment of $1.5 million contingent on certain product-related regulatory certifications obtained by May 26, 2024. As of September 30, 2022, the estimated fair value of the contingent earn-out is $1.8 million (see Note 9: Fair Value Measurements). During August 2021, we entered into an agreement with one of our international distributors whereby that distributor would not compete with us in a specific territory for a three-year period that will end in September 2024. The terms of the agreement include a contingent earn-out payment. The contingent earn-out shall not exceed $6.0 million, which will be earned based on certain revenue targets over a twelve-month measurement period determined by the highest four consecutive quarters commencing over a two-year period starting on the closing date of the agreement and provided that the distributor is in compliance with its obligations under the agreement. As of September 30, 2022, the estimated fair value of the contingent earn-out is $2.6 million (see Note 9: Fair Value Measurements). Commitments

Collaborative and Other Arrange

Collaborative and Other Arrangements (Notes)	9 Months Ended
	Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Collaborative Arrangement Disclosure [Text Block]	Collaborative and Other Arrangements    On February 3, 2017, we entered into two Manufacturing and Supply Agreements ("MSAs") whereby (i) Pfizer will manufacture and supply us with certain agreed upon products for an initial five-year term with a one-time two-year option to extend and (ii) we will manufacture and supply Pfizer certain agreed upon products for a term of five or ten years depending on the product, also with a one-time two-year option to extend. The MSAs provide each party with mutually beneficial interests and both of the MSAs are to be jointly managed by both Pfizer and ICU. The initial supply price, which is subject to an annual update, is in full consideration for all costs associated with the manufacture, documentation, packaging and certification of the products. On January 1, 2021, we amended our MSA with Pfizer, whereby we manufacture and supply certain agreed upon products to Pfizer. The amendments included a change to the term of the agreement to end on December 31, 2024 with Pfizer's unilateral election to extend through December 31, 2025. Other changes to the terms of the MSA included (i) amendments to our level of supply of products to Pfizer, (ii) certain changes to our manufacturing lines, (iii) updates to our supply price with added volume price tiers for annual periods and (iv) certain minimum purchase requirements for certain products. On February 1, 2022, effective as of January 1, 2022, upon our request, Pfizer executed a Product Addendum (the "Product Addendum") to our MSA, whereby Pfizer manufactures and supplies to us certain agreed upon products. The Product Addendum includes the supply of additional product to us subject to certain time and pricing terms and conditions. The Product Addendum includes a minimum purchase obligation of $29.6 million and expires on November 30, 2022. As of March 31, 2022, we had satisfied the minimum purchase obligations under the Product Addendum.

Equity

Equity	9 Months Ended
	Sep. 30, 2022
Equity [Abstract]
Stockholders' Equity Note Disclosure	Stockholders' Equity Shareholders Agreement At the completion of the Smiths Medical acquisition on January 6, 2022, Smiths owns approximately 10.5% of the total outstanding shares of our common stock (see Note 3: Acquisitions). At closing, in connection with the issuance of the share consideration, we entered into a Shareholders Agreement (the “Shareholders Agreement”) with Smiths. The Shareholders Agreement imposes certain restrictions on Smiths including prohibiting certain transfers of the shares of our common stock issued (i) for 6 months following the closing of the acquisition and (ii) to certain of our competitors and certain other parties, as well as customary standstill limitations. The Shareholders Agreement also permits Smiths to designate one individual for election to our Board of Directors (the "Board") so long as Smiths beneficially owns at least 5.0% of the total outstanding shares of our common stock. On February 1, 2022, our Board appointed a new director designated by Smiths pursuant to the Shareholders Agreement who was elected to the Board at the 2022 Annual Meeting of Stockholders held in May 2022. This appointment expanded the size of our Board from eight to nine members. See our Current Report on Form 8-K filed on February 1, 2022 for additional information. Treasury Stock In August 2019, our Board approved a share purchase plan to purchase up to $100.0 million of our common stock. This plan has no expiration date. During the three months ended September 30, 2022, we did not purchase any shares of our common stock under our share purchase plan. As of September 30, 2022, all of the $100.0 million available for purchase was remaining under the plan. We are currently limited on share purchases in accordance with the terms and conditions of our Credit Agreement (see Note 17: Long-Term Debt). For the nine months ended September 30, 2022, we withheld 45,370 shares of our common stock from employee vested restricted stock units in consideration for $10.5 million in payments made on the employees' behalf for their minimum statutory income tax withholding obligations. For the nine months ended September 30, 2021, we withheld 39,371 shares of our common stock from employee vested restricted stock units in consideration for $8.1 million in payments made on the employees' behalf for their minimum statutory income tax withholding obligations. Treasury stock is used to issue shares for stock option exercises and restricted stock grants. Accumulated Other Comprehensive (Loss) Income ("AOCI") The components of AOCI, net of tax, were as follows (in thousands): Foreign Currency Translation Adjustments Unrealized (Losses) Gains on Cash Flow Hedges Other Adjustments Total Balance as of January 1, 2022 $ (19,045) $ (237) $ 13 $ (19,269) Other comprehensive (loss) income before (4,946) 25,782 15 20,851 Amounts reclassified from AOCI — (2,210) — (2,210) Other comprehensive (loss) income (4,946) 23,572 15 18,641 Balance as of March 31, 2022 $ (23,991) $ 23,335 $ 28 $ (628) Other comprehensive (loss) income before reclassifications (99,805) 10,245 14 (89,546) Amounts reclassified from AOCI — (2,101) — (2,101) Other comprehensive (loss) income (99,805) 8,144 14 (91,647) Balance as of June 30, 2022 $ (123,796) $ 31,479 $ 42 $ (92,275) Other comprehensive (loss) income before reclassifications (90,549) 18,784 227 (71,538) Amounts reclassified from AOCI — (1,869) — (1,869) Other comprehensive (loss) income (90,549) 16,915 227 (73,407) Balance as of September 30, 2022 $ (214,345) $ 48,394 $ 269 $ (165,682) Foreign Currency Translation Adjustments Unrealized Gains (Losses) on Cash Flow Hedges Other Adjustments Total Balance as of January 1, 2021 $ (4,381) $ 2,784 $ 75 $ (1,522) Other comprehensive (loss) income before (7,458) (306) 12 (7,752) Amounts reclassified from AOCI — (639) — (639) Other comprehensive (loss) income (7,458) (945) 12 (8,391) Balance as of March 31, 2021 $ (11,839) $ 1,839 $ 87 $ (9,913) Other comprehensive income before reclassifications 1,302 335 12 1,649 Amounts reclassified from AOCI — (687) — (687) Other comprehensive income (loss) 1,302 (352) 12 962 Balance as of June 30, 2021 $ (10,537) $ 1,487 $ 99 $ (8,951) Other comprehensive (loss) income before reclassifications (5,360) (83) 12 (5,431) Amounts reclassified from AOCI — (736) — (736) Other comprehensive (loss) income (5,360) (819) 12 (6,167) Balance as of September 30, 2021 $ (15,897) $ 668 $ 111 $ (15,118)

Business Combinations and Ass_2

Business Combinations and Asset Acquisitions (Tables)	3 Months Ended
	Sep. 30, 2022
Business Combination and Asset Acquisition [Abstract]
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed	The following table summarizes the estimated purchase price and the preliminary allocation of the purchase price related to the assets acquired and liabilities assumed (in thousands): Estimated cash consideration for acquired assets $ 1,922,955 Preliminary fair value of contingent consideration payable to Smiths 53,520 Issuance of ICU Medical, Inc. common shares: Number of shares issued to Smiths 2,500 Price per share (ICU's opening market price on the acquisition date) $ 230.39 Fair value of ICU shares issued to Smiths $ 575,975 Total estimated consideration to be paid $ 2,552,450 Preliminary Purchase Price Allocation: Cash and cash equivalents $ 78,791 Accounts receivable 118,522 Inventories 226,196 Prepaid expenses and other current assets 53,554 Property, plant and equipment 210,000 Operating lease right-of-use assets 55,161 Intangible assets (1) 975,000 Deferred income taxes 9,303 Other assets 379 Accounts payable (105,291) Accrued liabilities (2) (173,901) Income tax payable (24,332) Other long-term liabilities (85,739) Deferred income taxes (235,170) Total identifiable net assets acquired $ 1,102,473 Goodwill - not tax deductible 1,449,977 Estimated Purchase Consideration $ 2,552,450 _______________________________ (1) Estimated identifiable intangible assets include $540.0 million of customer relationships, $400.0 million of developed technology, $30.0 million of internally developed software, and $5.0 million of trademark. The estimated weighted-average amortization period for the total identifiable intangible assets is approximately nine eight ten five six (2) Estimated accrued liabilities includes, among other things, accrued warranty reserves, accrued restructuring initiatives, accrued salaries and related benefits, deferred revenue and accrued sales and use taxes.
Business Acquisition, Pro Forma Information	Three months ended September 30, Nine months ended September 30, (In thousands) 2022 2021 2022 2021 Revenues $ 597,857 $ 641,115 $ 1,722,357 $ 1,862,237 Net Loss $ (13,208) $ (8,874) $ (54,840) $ 22,026

Restructuring, Strategic Tran_2

Restructuring, Strategic Transaction and Integration (Tables)	9 Months Ended
	Sep. 30, 2022
Restructuring and Related Activities [Abstract]
Restructuring and Related Costs [Table Text Block]	The following table summarizes the activity in our restructuring-related accrual by major type of cost for the period ended September 30, 2022 (in thousands): Severance Pay and Benefits Retention and Facility Closure Costs Total Accrued balance, January 1, 2022 $ 499 $ 165 $ 664 Acquired restructuring liabilities 5,796 1,740 7,536 Charges incurred 3,222 — 3,222 Payments (2,030) — (2,030) Currency translation (147) (40) (187) Accrued balance, March 31, 2022 $ 7,340 $ 1,865 $ 9,205 Charges incurred 1,710 — 1,710 Payments (3,352) (212) (3,564) Currency translation (256) (94) (350) Other adjustments (38) — (38) Accrued balance, June 30, 2022 $ 5,404 $ 1,559 $ 6,963 Charges incurred 2,428 — 2,428 Payments (2,181) (19) (2,200) Currency translation (310) (114) (424) Accrued balance, September 30, 2022 $ 5,341 $ 1,426 $ 6,767

Revenue (Tables)

Revenue (Tables)	9 Months Ended
	Sep. 30, 2022
Revenue from Contract with Customer [Abstract]
Disaggregation of Revenue [Table Text Block]	The following table represents our revenues disaggregated by geography (in thousands): Three months ended Nine months ended Geography 2022 2021 2022 2021 United States $ 376,691 $ 245,298 $ 1,088,348 $ 697,316 Canada 29,129 19,026 86,473 61,560 LATAM 23,599 14,875 59,827 44,191 Americas 429,419 279,199 1,234,648 803,067 Europe, the Middle East and Africa 101,869 36,239 275,488 108,800 APAC 66,569 20,622 191,847 63,916 Total Revenues $ 597,857 $ 336,060 $ 1,701,983 $ 975,783
Contract with Customer, Asset and Liability [Table Text Block]	The following table presents the changes in our contract balances for the nine months ended September 30, 2022 and 2021 (in thousands): Contract Liabilities Beginning balance, January 1, 2022 $ (7,461) Fair value of acquired deferred revenue (51,245) Equipment revenue recognized 22,757 Equipment revenue deferred due to implementation (13,420) Software revenue recognized 12,761 Software revenue deferred due to implementation (12,978) Government grant deferred revenue (3,434) Government grant recognized 178 Other deferred revenue (1,285) Other deferred revenue recognized 3,488 Ending balance, September 30, 2022 $ (50,639) Beginning balance, January 1, 2021 $ (6,430) Equipment revenue recognized 7,193 Equipment revenue deferred due to implementation (8,652) Software revenue recognized 6,194 Software revenue deferred due to implementation (2,967) Ending balance, September 30, 2021 $ (4,662)

Leases (Tables)

Leases (Tables)	9 Months Ended
	Sep. 30, 2022
Leases [Abstract]
Lease, Cost [Table Text Block]	The following table presents the components of our lease cost (in thousands): Three months ended Nine months ended 2022 2021 2022 2021 Operating lease cost $ 5,819 $ 2,798 $ 16,472 $ 8,455 Finance lease cost — interest 25 29 82 92 Finance lease cost — reduction of ROU asset 176 166 516 478 Short-term lease cost 1 4 7 14 Total lease cost $ 6,021 $ 2,997 $ 17,077 $ 9,039
Cash Flow, Supplemental Disclosures [Text Block]	The following table presents the supplemental cash flow information related to our leases (in thousands): Nine months ended 2022 2021 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 18,886 $ 8,461 Operating cash flows from finance leases $ 25 $ 29 Right-of-use assets obtained in exchange for lease obligations: Operating leases $ 4,771 $ 1,394 Finance leases $ 266 $ 373
Assets and Liabilities, Leases [Table Text Block]	The following table presents the supplemental balance sheet information related to our operating leases (in thousands, except lease term and discount rate): As of September 30, 2022 December 31, 2021 Operating leases Operating lease right-of-use assets $ 76,438 $ 39,847 Accrued liabilities $ 18,638 $ 9,009 Other long-term liabilities 62,902 33,971 Total operating lease liabilities $ 81,540 $ 42,980 Weighted-Average Remaining Lease Term Operating leases 6.1 years 5.9 years Weighted-Average Discount Rate Operating leases 4.38 % 4.98 % The following table presents the supplemental balance sheet information related to our finance leases (in thousands, except lease term and discount rate): As of September 30, 2022 December 31, 2021 Finance leases Finance lease right-of-use assets $ 2,327 $ 2,673 Accrued liabilities $ 700 $ 643 Other long-term liabilities 1,692 2,067 Total finance lease liabilities $ 2,392 $ 2,710 Weighted-Average Remaining Lease Term Finance leases 4.9 years 5.6 years Weighted-Average Discount Rate Finance leases 4.26 % 4.28 %
Lessee, Operating Lease, Liability, Maturity [Table Text Block]	As of September 30, 2022, the maturities of our operating and finance lease liabilities for each of the next five years are approximately (in thousands): Operating Leases Finance Leases Remainder of 2022 $ 6,129 $ 197 2023 20,915 790 2024 17,157 524 2025 12,233 317 2026 10,980 217 2027 7,638 189 Thereafter 16,600 426 Total Lease Payments 91,652 2,660 Less imputed interest (10,112) (268) Total $ 81,540 $ 2,392

Net Income Per Share (Tables)

Net Income Per Share (Tables)	9 Months Ended
	Sep. 30, 2022
Earnings Per Share [Abstract]
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	The following table presents the calculation of net earnings per common share (“EPS”) — basic and diluted (in thousands, except per share data): Three months ended Nine months ended 2022 2021 2022 2021 Net (loss) income $ (13,208) $ 31,081 $ (58,750) $ 83,210 Weighted-average number of common shares outstanding (basic) 23,908 21,214 23,828 21,189 Dilutive securities (1) — 516 — 546 Weighted-average common and common equivalent shares outstanding (diluted) 23,908 21,730 23,828 21,735 EPS — basic $ (0.55) $ 1.47 $ (2.47) $ 3.93 EPS — diluted $ (0.55) $ 1.43 $ (2.47) $ 3.83 _______________________________ (1) No dilutive effect for the three and nine months ended September 30, 2022; therefore, zero incremental shares included for the period.

Derivative Financial Instrume_2

Derivative Financial Instruments (Tables)	9 Months Ended
	Sep. 30, 2022
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of Cash Flow Hedging Instruments, Statements of Financial Performance and Financial Position, Location [Table Text Block]	The following table presents the fair values of our derivative instruments included within the Condensed Consolidated Balance Sheets (in thousands): Derivatives Designated as Cash Flow Hedging Instruments Condensed Consolidated Balance Sheet Location Foreign Exchange Contracts Interest Rate Swaps Gross Derivatives As of September 30, 2022 Prepaid expenses and other current assets $ 11,695 $ 24,924 $ 36,619 Other assets — 33,386 33,386 Total assets $ 11,695 $ 58,310 $ 70,005 Accrued liabilities $ 1,752 $ — $ 1,752 Other long-term liabilities — — — Total liabilities $ 1,752 $ — $ 1,752 As of December 31, 2021 Prepaid expenses and other current assets $ 1,061 $ — $ 1,061 Other assets — — — Total assets $ 1,061 $ — $ 1,061 Accrued liabilities $ — $ — $ — Other long-term liabilities — 1,480 1,480 Total liabilities $ — $ 1,480 $ 1,480 We recognized the following gains on our derivative instruments designated as cash flow hedges (in thousands): Gain (Loss) Recognized in Other Comprehensive Income Three months ended Nine months ended 2022 2021 2022 2021 Derivatives designated as cash flow hedging instruments: Foreign exchange contracts $ 3,383 $ (109) $ 11,720 $ (70) Interest rate swaps 21,201 — 60,398 — Total derivatives designated as cash flow hedging instruments $ 24,584 $ (109) $ 72,118 $ (70)
Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss) [Table Text Block]	Gain (Loss) Reclassified From Accumulated Other Comprehensive (Loss) Income into Income Three months ended Nine months ended Location of Gain (Loss) Recognized in Income 2022 2021 2022 2021 Derivatives designated as cash flow hedging instruments: Foreign exchange contracts Total revenues $ (1,690) $ — $ 2,666 $ — Foreign exchange contracts Cost of goods sold 3,090 968 4,140 2,713 Foreign exchange contracts Interest expense (1) 462 — 717 — Interest rate swaps Interest expense 2,133 — 608 — Total derivatives designated as cash flow hedging instruments $ 3,995 $ 968 $ 8,131 $ 2,713 _______________________________ (1) Represents location of gain reclassified from accumulated other comprehensive income into income as a result of a forecasted transaction being no longer probable of occurring.

Fair Value Measures and Discl_2

Fair Value Measures and Disclosures (Tables)	9 Months Ended
	Sep. 30, 2022
Fair Value Disclosures [Abstract]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation	The following tables provide a reconciliation of the Level 3 earn-out liabilities measured at estimated fair value (in thousands): Earn-out Liability Accrued balance, January 1, 2022 $ 2,589 Acquisition date fair value estimate of earn-out (1) 55,158 Currency translation (46) Accrued balance, March 31, 2022 $ 57,701 Change in fair value of earn-out (included in income from operations as a separate line item) (2) (27,194) Currency translation (98) Accrued balance, June 30, 2022 $ 30,409 Change in fair value of earn-out (included in income from operations as a separate line item) (2) (4,059) Currency translation (108) Accrued balance, September 30, 2022 $ 26,242 _______________________________ (1) $53.5 million relates to our acquisition of Smiths Medical and $1.6 million relates to our acquisition of a small foreign infusions systems supplier in the fourth quarter of 2021 (see Note 3: Acquisitions). (2) Primarily relates to the change in fair value of the Smiths Medical earn-out. Earn-out Liability Accrued balance, January 1, 2021 $ 26,300 Change in fair value of earn-out (included in income from operations as a separate line item) — Accrued balance, March 31, 2021 $ 26,300 Change in fair value of earn-out (included in income from operations as a separate line item) — Accrued balance, June 30, 2021 $ 26,300 Contingent earn-out — non-compete arrangement 3,100 Transfer of Pursuit earn-out liability into Level 2 (26,300) Accrued balance, September 30, 2021 $ 3,100
Fair Value Measurement Inputs and Valuation Techniques	The following tables provide quantitative information about Level 3 inputs for fair value measurement of our earn-out liabilities related to Smiths Medical and Pursuit: Smiths Medical Earn-out Simulation Input As of At Acquisition Volatility 42.00 % 37.00 % Risk-Free Rate 4.18 % 1.31 % Pursuit Earn-out Simulation Input As of Revenue/Gross Profit Volatility 25.00 % Discount Rate 12.50 % Risk-Free Rate 0.09 % Counter Party Risk 3.10 %
Fair Value, by Balance Sheet Grouping	Our assets and liabilities measured at fair value on a recurring basis consisted of the following Level 1, 2 and 3 inputs as defined above (in thousands): Fair value measurements as of September 30, 2022 Total carrying Quoted prices Significant Significant Assets: Available-for-sale debt securities: Short-term corporate bonds $ 1,511 $ — $ 1,511 $ — Short-term U.S. treasury securities 1,408 1,408 — — Long-term corporate bonds 1,333 — 1,333 — Long-term government bonds 498 — 498 — Foreign exchange contracts: Prepaid expenses and other current assets 11,695 — 11,695 — Other assets — — — — Interest rate contracts: Prepaid expenses and other current assets 24,924 — 24,924 — Other assets 33,386 — 33,386 — Total Assets $ 74,755 $ 1,408 $ 73,347 $ — Liabilities: Contingent earn-out liability - ST $ 300 $ — $ — $ 300 Contingent earn-out liability - LT 25,942 — — 25,942 Foreign exchange contracts: Accrued liabilities 1,752 — 1,752 — Total Liabilities $ 27,994 $ — $ 1,752 $ 26,242 Fair value measurements as of December 31, 2021 Total carrying Quoted prices Significant Significant Assets: Available-for-sale debt securities: Short-term corporate bonds $ 14,420 $ — $ 14,420 $ — Long-term corporate bonds 4,620 — 4,620 — Cross-currency par forward contract: Prepaid expenses and other current assets 1,061 — 1,061 — Total Assets $ 20,101 $ — $ 20,101 $ — Liabilities: Contingent earn-out liability - LT $ 2,589 $ — $ — $ 2,589 Forward-starting interest rate swaps: Other long-term liabilities 1,480 — 1,480 — Total Liabilities $ 4,069 $ — $ 1,480 $ 2,589

Investment Securities (Tables)

Investment Securities (Tables)	9 Months Ended
	Sep. 30, 2022
Investments, Debt and Equity Securities [Abstract]
Schedule of Available-for-sale Securities Reconciliation [Table Text Block]	Our short-term and long-term investments in available-for-sale securities consist of the following (in thousands): As of September 30, 2022 Amortized Cost Unrealized Holding Fair Value Short-term corporate bonds $ 1,511 $ — $ 1,511 Short-term U.S. treasury securities 1,408 — 1,408 Long-term corporate bonds 1,333 — 1,333 Long-term government bonds 498 — 498 Total investment securities $ 4,750 $ — $ 4,750 As of December 31, 2021 Amortized Cost Unrealized Holding Fair Value Short-term corporate bonds $ 14,420 $ — $ 14,420 Long-term corporate bonds 4,620 — 4,620 Total investment securities $ 19,040 $ — $ 19,040
Equity Method Investments [Table Text Block]	Our non-marketable equity method investment consists of the following (in thousands): As of September 30, 2022 December 31, 2021 Equity method investment $ 3,188 $ 3,238 Investments in non-marketable debt securities During the second quarter 2022, we received $19.0 million in proceeds from a promissory note related to an acquired investment as part of the Smiths Medical acquisition.

Prepaids and Other Current As_2

Prepaids and Other Current Assets (Tables)	9 Months Ended
	Sep. 30, 2022
Prepaid Expense and Other Assets [Abstract]
Prepaid Expenses and Other Current Assets [Table Text Block]	Prepaid expenses and other current assets consist of the following (in thousands): As of September 30, 2022 December 31, 2021 Other prepaid expenses and receivables $ 22,738 $ 14,763 Prepaid vendor expenses 2,641 — Deferred costs 3,775 12,746 Prepaid insurance and property taxes 14,019 6,310 VAT/GST receivable 2,946 4,156 Deferred tax charge 4,452 4,241 Foreign exchange contracts 11,695 1,061 Interest rate contracts 24,924 — Interest receivable 2,426 293 Deposits 1,312 1,343 Other 3,355 1,934 $ 94,283 $ 46,847
Schedule of Other Assets, Noncurrent[TableTextBlock]	Other assets consist of the following (in thousands): As of September 30, 2022 December 31, 2021 Pump lease receivables $ 27,024 $ 25,941 Spare parts 36,937 28,538 Equity method investments 3,188 3,238 Deferred debt issuance costs 5,586 2,827 Finance lease right-of-use assets 2,327 2,673 Interest rate contracts 33,386 — Other 2,156 526 $ 110,604 $ 63,743

Inventories (Tables)

Inventories (Tables)	9 Months Ended
	Sep. 30, 2022
Inventory Disclosure [Abstract]
Schedule of Inventory, Current [Table Text Block]	Inventories consist of the following (in thousands): As of September 30, 2022 December 31, 2021 Raw materials $ 264,518 $ 135,528 Work in process 71,367 36,490 Finished goods 289,383 118,217 Total inventories $ 625,268 $ 290,235 During 2022, inventories increased significantly due to the acquisition of Smiths Medical. All acquired inventory was recorded at fair value on January 6, 2022 in accordance with ASC 805, Business Combinations (see Note 3: Acquisitions).

Property and Equipment (Tables)

Property and Equipment (Tables)	9 Months Ended
	Sep. 30, 2022
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment [Table Text Block]	Property, plant and equipment consists of the following (in thousands): As of September 30, 2022 December 31, 2021 Machinery and equipment $ 409,349 $ 321,078 Land, building and building improvements 272,426 243,377 Molds 75,874 60,463 Computer equipment and software 114,378 102,979 Furniture and fixtures 29,110 7,670 Instruments placed with customers (1) 106,245 97,384 Construction in progress 147,099 72,153 Total property, plant and equipment, cost 1,154,481 905,104 Accumulated depreciation (498,098) (436,739) Property, plant and equipment, net $ 656,383 $ 468,365

Goodwill and Intangible Asset_2

Goodwill and Intangible Assets (Tables)	9 Months Ended
	Sep. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Goodwill [Table Text Block]	The following table presents the changes in the carrying amount of our goodwill (in thousands): Total Balance as of January 1, 2022 $ 43,439 Goodwill acquired (1) 1,449,977 Other (2) (7,128) Currency translation (116,571) Balance as of September 30, 2022 $ 1,369,717 _______________________________ (1) Relates to Smiths Medical acquired on January 6, 2022. (2) Other reflects measurement period adjustments related to a 2021 acquisition of a small foreign infusion systems supplier.
Schedule of Intangible Assets and Goodwill [Table Text Block]	Intangible assets, carried at cost less accumulated amortization and amortized on a straight-lined basis, were as follows (in thousands): Weighted-Average Amortization Life in Years September 30, 2022 Cost Accumulated Net Patents 10 $ 29,301 $ 18,135 $ 11,166 Customer contracts 12 9,909 6,339 3,570 Non-contractual customer relationships 8 560,691 85,081 475,610 Trademarks 1 5,425 5,425 — Trade name 15 18,244 5,643 12,601 Developed technology 10 576,687 93,490 483,197 Non-compete 3 9,100 4,631 4,469 Total amortized intangible assets $ 1,209,357 $ 218,744 $ 990,613 Internally developed software* $ 30,045 $ 30,045 Total intangible assets $ 1,239,402 $ 218,744 $ 1,020,658 ______________________________ * Internally developed software will be amortized when the projects are complete and the assets are ready for their intended use. Weighted-Average Amortization Life in Years December 31, 2021 Cost Accumulated Net Patents 10 $ 27,429 $ 16,764 $ 10,665 Customer contracts 12 10,412 6,196 4,216 Non-contractual customer relationships 9 57,316 33,004 24,312 Trademarks 4 425 425 — Trade name 15 18,260 4,731 13,529 Developed technology 13 152,893 49,406 103,487 Non-compete 3 9,100 2,356 6,744 Total amortized intangible assets $ 275,835 $ 112,882 $ 162,953 Internally developed software* $ 25,358 $ 25,358 Total intangible assets $ 301,193 $ 112,882 $ 188,311
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]	As of September 30, 2022 estimated annual amortization for our intangible assets for each of the next five years is approximately (in thousands): Remainder of 2022 $ 33,624 2023 132,368 2024 131,729 2025 123,901 2026 123,502 2027 115,491 Thereafter 329,998 Total $ 990,613

Accrued Liabilities (Tables)

Accrued Liabilities (Tables)	9 Months Ended
	Sep. 30, 2022
Accrued Liabilities [Abstract]
Schedule of Accrued Liabilities [Table Text Block]	Accrued liabilities consist of the following (in thousands): As of September 30, 2022 December 31, 2021 Salaries and benefits $ 49,409 $ 27,304 Incentive compensation 24,388 33,107 Operating lease liability-ST 18,638 9,009 Accrued sales taxes 6,507 1,980 Restructuring accrual 6,767 664 Deferred revenue 31,183 12,646 Accrued other taxes 4,415 4,337 Accrued professional fees 8,694 773 Legal accrual 4,240 3,897 Distribution fees 25,326 5,645 Warranties and returns 3,059 532 Field service corrective action (1) 24,857 — Accrued freight 14,234 9,194 Foreign exchange contracts 1,752 — Accrued audit fees 6,095 1,008 Defined benefit plan 2,527 — Accrued interest 2,788 — Other 9,424 8,099 $ 244,303 $ 118,195 ___________________________ (1) Relates to field corrective actions associated with certain products in connection with a 2021 Warning Letter received by Smiths Medical from the FDA following an inspection of Smiths Medical’s Oakdale, Minnesota Facility, see Note 19: Commitments and Contingencies for further detail. As of September 30, 2022 December 31, 2021 Operating lease liability-LT $ 62,902 $ 33,971 Benefits 5,958 1,369 Accrued rent 1,030 1,262 Forward-starting interest rate swaps — 1,480 Finance lease liability-LT 1,692 2,067 Deferred revenue 21,976 — Field service corrective action (1) 22,620 — Other 3,073 1,681 $ 119,251 $ 41,830

Long-Term Obligations (Tables)

Long-Term Obligations (Tables)	3 Months Ended
	Sep. 30, 2022
LOng-Term Obligations Disclosure [Abstract]
Schedule of Long-term Debt Instruments	The carrying values of our long-term debt consist of the following (in thousands): Effective Interest Rate As of Senior Secured Credit Facilities: Term Loan A — principal 3.39 % $ 834,000 Term Loan B — principal 3.98 % 845,750 Revolving Credit Facility — principal — % — Less unamortized debt issuance costs (1) (25,526) Total carrying value of long-term debt 1,654,224 Less current portion of long-term debt 24,375 Long-term debt, net $ 1,629,849 _______________________________ (1) Comprised of $13.4 million and $12.2 million relating to the Term Loan A and the Term Loan B, respectively.
Schedule of Maturities of Long-term Debt	As of September 30, 2022, the aggregate amount of principal repayments of our long-term debt (including any current portion) for each of the next five years is approximately (in thousands): Remainder of 2022 $ 2,125 2023 29,750 2024 51,000 2025 51,000 2026 72,250 2027 672,500 Thereafter 801,125 Total $ 1,679,750
Interest expense on long term debt	The following table presents the total interest expense related to our long-term debt (in thousands): Three months ended Nine months ended 2022 2021 2022 2021 Contractual interest $ 19,228 $ — $ 41,868 $ — Amortization of debt issuance costs 1,758 72 5,200 216 Commitment fee — Revolving Credit Facility 334 58 994 171 Total long-term debt-related interest expense $ 21,320 $ 130 48,062 387
Applicable Margin Based on Leverage Ratio	Effective on the first Adjustment Date, as defined in the Credit Agreement, occurring subsequent to our quarter ending June 30, 2022, the applicable margin for the Term Loan A and borrowings under the Revolving Credit Facility will be determined by reference to the leverage ratio in effect from time to time as set forth in the following table: Leverage Ratio Applicable Margin for Term SOFR Loans Applicable Margin for Base Rate Loans Commitment Fee Rate Greater than 4.00 to 1.0 2.25% 1.25% 0.35% Less than or equal to 4.00 to 1.0 but greater than 3.00 to 1.0 2.00% 1.00% 0.30% Less than or equal to 3.00 to 1.0 but greater than 2.50 to 1.0 1.75% 0.75% 0.25% Less than or equal to 2.50 to 1.0 but greater than 2.00 to 1.0 1.50% 0.50% 0.20% Less than or equal to 2.00 to 1.0 1.25% 0.25% 0.15%

Equity (Tables)

Equity (Tables)	9 Months Ended
	Sep. 30, 2022
Equity [Abstract]
Schedule of Accumulated Other Comprehensive Income (Loss)	The components of AOCI, net of tax, were as follows (in thousands): Foreign Currency Translation Adjustments Unrealized (Losses) Gains on Cash Flow Hedges Other Adjustments Total Balance as of January 1, 2022 $ (19,045) $ (237) $ 13 $ (19,269) Other comprehensive (loss) income before (4,946) 25,782 15 20,851 Amounts reclassified from AOCI — (2,210) — (2,210) Other comprehensive (loss) income (4,946) 23,572 15 18,641 Balance as of March 31, 2022 $ (23,991) $ 23,335 $ 28 $ (628) Other comprehensive (loss) income before reclassifications (99,805) 10,245 14 (89,546) Amounts reclassified from AOCI — (2,101) — (2,101) Other comprehensive (loss) income (99,805) 8,144 14 (91,647) Balance as of June 30, 2022 $ (123,796) $ 31,479 $ 42 $ (92,275) Other comprehensive (loss) income before reclassifications (90,549) 18,784 227 (71,538) Amounts reclassified from AOCI — (1,869) — (1,869) Other comprehensive (loss) income (90,549) 16,915 227 (73,407) Balance as of September 30, 2022 $ (214,345) $ 48,394 $ 269 $ (165,682) Foreign Currency Translation Adjustments Unrealized Gains (Losses) on Cash Flow Hedges Other Adjustments Total Balance as of January 1, 2021 $ (4,381) $ 2,784 $ 75 $ (1,522) Other comprehensive (loss) income before (7,458) (306) 12 (7,752) Amounts reclassified from AOCI — (639) — (639) Other comprehensive (loss) income (7,458) (945) 12 (8,391) Balance as of March 31, 2021 $ (11,839) $ 1,839 $ 87 $ (9,913) Other comprehensive income before reclassifications 1,302 335 12 1,649 Amounts reclassified from AOCI — (687) — (687) Other comprehensive income (loss) 1,302 (352) 12 962 Balance as of June 30, 2021 $ (10,537) $ 1,487 $ 99 $ (8,951) Other comprehensive (loss) income before reclassifications (5,360) (83) 12 (5,431) Amounts reclassified from AOCI — (736) — (736) Other comprehensive (loss) income (5,360) (819) 12 (6,167) Balance as of September 30, 2021 $ (15,897) $ 668 $ 111 $ (15,118)

Business Combinations and Ass_3

Business Combinations and Asset Acquisitions Foreign Infusion Distributor(Details) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2022
Business Acquisition [Line Items]
Payments to Acquire Businesses, Gross		$ 1,922,955
Contingent Consideration, Gross ST	$ 1,000
Contingent Consideration, Gross LT	1,500
Business Combination, Consideration, Holdback liability	500
Foreign Infusion System Supplier
Business Acquisition [Line Items]
Payments to Acquire Businesses, Gross	15,400
contingent consideration gross	2,500
Contingent Consideration, Gross ST	1,000
Contingent Consideration, Gross LT	$ 1,500
Business Combination, Consideration Transferred		$ 17,100

Business Combinations and Ass_4

Business Combinations and Asset Acquisitions (Details) - USD ($) shares in Thousands	9 Months Ended
	Sep. 30, 2022	Dec. 31, 2021	[1]
Business Acquisition [Line Items]
Contingent Earn-Out Liability, Noncurrent	$ 25,942,000	$ 2,589,000
Minimum Stock Price Target for Earn-out Payment	$ 300
Required Share Holding Of Stock Issued At Acquisition	0.500
SmithsMedical
Business Acquisition [Line Items]
Business Acquisition, Percentage of Voting Interests Acquired	100%
Business Combination, Consideration Transferred, Cash	$ 1,900,000,000
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares	2,500
Contingent Earn-Out Liability, Noncurrent	$ 100,000,000
[1]December 31, 2021 balances were derived from audited consolidated financial statements.

Business Combinations and Ass_5

Business Combinations and Asset Acquisitions Smiths Medical (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Mar. 31, 2022	Sep. 30, 2022
Business Acquisition [Line Items]
Payments to Acquire Businesses, Gross			$ 1,922,955
Business Combination, Consideration Transferred, Liabilities Incurred		$ 55,158
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life			9 years
Customer Relationships
Business Acquisition [Line Items]
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life			8 years
Technology-Based Intangible Assets
Business Acquisition [Line Items]
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life			10 years
Software Development
Business Acquisition [Line Items]
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life			5 years
Trademarks [Member]
Business Acquisition [Line Items]
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life			6 years
SmithsMedical
Business Acquisition [Line Items]
Business Combination, Consideration Transferred, Liabilities Incurred		$ 53,500	$ 53,520
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares			2,500
Business Acquisition, Share Price	$ 230.39		$ 230.39
Business Acquisition, Equity Interest Issued or Issuable, Value Assigned	$ 575,975		$ 575,975
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents	78,791		78,791
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables	118,522		118,522
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory	226,196		226,196
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets	53,554		53,554
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment	210,000		210,000
business combination, recognized identifiable asset acquired and liability assumed,	55,161		55,161
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	975,000		975,000
Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Assets	9,303		9,303
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets	379		379
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable	105,291		105,291
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities	173,901		173,901
Business Combinations, Identified Assumed Liabilities Recognized, Income tax payable	(24,332)		(24,332)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other	(85,739)		(85,739)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities	(235,170)		(235,170)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net	1,102,473		1,102,473
Business combination, goodwill- non deductible	1,449,977		1,449,977
Business Combination, Consideration Transferred	2,552,450		2,552,450
SmithsMedical | Customer Relationships
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	540,000		540,000
SmithsMedical | developed technology
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	400,000		400,000
SmithsMedical | Trademarks and Trade Names
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	5,000		5,000
SmithsMedical | Software and Software Development Costs
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	$ 30,000		$ 30,000

Business Combinations and Ass_6

Business Combinations and Asset Acquisitions Smiths Medical Pro Forma (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Business Combination and Asset Acquisition [Abstract]
Business Acquisition, Pro Forma Revenue	$ 597,857	$ 641,115	$ 1,722,357	$ 1,862,237
Business Acquisition [Line Items]
Revenues	597,857	336,060	1,701,983	975,783
Net (Loss) Income	(13,208)	31,081	(58,750)	83,210
Business Acquisition, Pro Forma Net Income (Loss)	(13,208)	(8,874)	(54,840)	$ 22,026
Pro Forma Adjustment - Amortization	1,900	1,900
Pro Forma Adjustment - Finance Costs	1,400	47,100
Pro Forma Adjustment - Inventory		$ 27,400
Acquisition-related Costs
Business Acquisition [Line Items]
Business Acquisition, Transaction Costs	11,600		11,600
SmithsMedical
Business Acquisition [Line Items]
Revenues	261,400		699,100
Net (Loss) Income	$ 13,600		$ 79,000

Restructuring, Strategic Tran_3

Restructuring, Strategic Transaction and Integration Restructuring (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Restructuring and Related Activities [Abstract]
Restructuring, strategic transaction and integration	$ 14,400	$ 2,400	$ 61,800	$ 9,000
Restructuring Costs		$ 2,400	$ 7,300

Restructuring, Strategic Tran_4

Restructuring, Strategic Transaction and Integration Liability (Details) - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve	$ 6,963	$ 9,205	$ 664
Acquired Restructuring Liabilities			7,536
Restructuring Charges	2,428	1,710	3,222
Payments for Restructuring	2,200	3,564	2,030
Restructuring Reserve, Foreign Currency Translation Gain (Loss)	424	350	187
Restructuring Reserve, Accrual Adjustment		(38)
Restructuring Reserve	6,767	6,963	9,205
Employee Severance [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve	5,404	7,340	499
Acquired Restructuring Liabilities			5,796
Restructuring Charges	2,428	1,710	3,222
Payments for Restructuring	2,181	3,352	2,030
Restructuring Reserve, Foreign Currency Translation Gain (Loss)	310	256	147
Restructuring Reserve, Accrual Adjustment		(38)
Restructuring Reserve	5,341	5,404	7,340
Facility Closing [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve	1,559	1,865	165
Acquired Restructuring Liabilities			1,740
Restructuring Charges	0	0	0
Payments for Restructuring	19	212	0
Restructuring Reserve, Foreign Currency Translation Gain (Loss)	114	94	40
Restructuring Reserve, Accrual Adjustment		0
Restructuring Reserve	$ 1,426	$ 1,559	$ 1,865

Strategic Transaction and Integ

Strategic Transaction and Integration (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Restructuring and Related Activities [Abstract]
Strategic Transaction and Integration	$ 12	$ 4.3	$ 54.5	$ 10.8

Revenue Disaggregated Revenue b

Revenue Disaggregated Revenue by Geography (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Disaggregation of Revenue [Line Items]
Revenues	$ 597,857	$ 336,060	$ 1,701,983	$ 975,783
EMEA [Member]
Disaggregation of Revenue [Line Items]
Revenues	101,869	36,239	275,488	108,800
UNITED STATES
Disaggregation of Revenue [Line Items]
Revenues	376,691	245,298	1,088,348	697,316
CANADA
Disaggregation of Revenue [Line Items]
Revenues	29,129	19,026	86,473	61,560
Latin America
Disaggregation of Revenue [Line Items]
Revenues	23,599	14,875	59,827	44,191
Asia Pacific
Disaggregation of Revenue [Line Items]
Revenues	66,569	20,622	191,847	63,916
Americas
Disaggregation of Revenue [Line Items]
Revenues	$ 429,419	$ 279,199	$ 1,234,648	$ 803,067

Revenue Disaggregated Revenue_2

Revenue Disaggregated Revenue by Product Line (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Disaggregation of Revenue [Line Items]
Revenues	$ 597,857	$ 336,060	$ 1,701,983	$ 975,783
Infusion Consumables [Member]
Disaggregation of Revenue [Line Items]
Revenues	141,073	144,850	426,050	407,419
Infusion Systems [Member]
Disaggregation of Revenue [Line Items]
Revenues	87,846	90,688	262,111	259,683
IV Solutions [Member]
Disaggregation of Revenue [Line Items]
Revenues	96,366	89,237	278,959	271,834
Critical Care [Member]
Disaggregation of Revenue [Line Items]
Revenues	10,877	11,285	35,407	36,847
Infusion Consumables-Smiths Medical
Disaggregation of Revenue [Line Items]
Revenues	96,890	0	240,992	0
Vascular Access
Disaggregation of Revenue [Line Items]
Revenues	95,284	0	251,350	0
Vital Care
Disaggregation of Revenue [Line Items]
Revenues	$ 69,521	$ 0	$ 207,114	$ 0

Revenue Contract Liabilities (D

Revenue Contract Liabilities (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Movement in Deferred Revenue [Roll Forward]
Contract with Customer, Liability	$ (7,461)	$ (6,430)
Contract with Customer, Liability	(50,639)	(4,662)
Short Term
Movement in Deferred Revenue [Roll Forward]
Revenue, Remaining Performance Obligation, Amount	(28,776)
Long Term
Movement in Deferred Revenue [Roll Forward]
Revenue, Remaining Performance Obligation, Amount	(21,863)
SmithsMedical
Movement in Deferred Revenue [Roll Forward]
Contract with Customer, Liability		(51,245)
Equipment revenue [Member]
Movement in Deferred Revenue [Roll Forward]
Increase (Decrease) in Deferred Revenue	22,757	7,193
Deferred Revenue, Additions	(13,420)	(8,652)
Equipment revenue [Member] | Short Term
Movement in Deferred Revenue [Roll Forward]
Revenue, Remaining Performance Obligation, Amount	(17,514)
Equipment revenue [Member] | Long Term
Movement in Deferred Revenue [Roll Forward]
Revenue, Remaining Performance Obligation, Amount	(621)
Software revenue [Member]
Movement in Deferred Revenue [Roll Forward]
Increase (Decrease) in Deferred Revenue	12,761	6,194
Deferred Revenue, Additions	(12,978)	$ (2,967)
Software revenue [Member] | Short Term
Movement in Deferred Revenue [Roll Forward]
Revenue, Remaining Performance Obligation, Amount	(8,248)
Software revenue [Member] | Long Term
Movement in Deferred Revenue [Roll Forward]
Revenue, Remaining Performance Obligation, Amount	(566)
Government Grant Revenue
Movement in Deferred Revenue [Roll Forward]
Increase (Decrease) in Deferred Revenue	178
Deferred Revenue, Additions	(3,434)
Government Grant Revenue | Short Term
Movement in Deferred Revenue [Roll Forward]
Revenue, Remaining Performance Obligation, Amount	(1,524)
Government Grant Revenue | Long Term
Movement in Deferred Revenue [Roll Forward]
Revenue, Remaining Performance Obligation, Amount	(13,735)
Other deferred revenue
Movement in Deferred Revenue [Roll Forward]
Increase (Decrease) in Deferred Revenue	3,488
Deferred Revenue, Additions	(1,285)
Other deferred revenue | Short Term
Movement in Deferred Revenue [Roll Forward]
Revenue, Remaining Performance Obligation, Amount	(1,490)
Other deferred revenue | Long Term
Movement in Deferred Revenue [Roll Forward]
Revenue, Remaining Performance Obligation, Amount	$ (6,941)

Leases Text (Details)

Leases Text (Details)	9 Months Ended
	Sep. 30, 2022
Lessee, Lease, Description [Line Items]
Lessee, Operating Lease, Option to Extend	5 years
Maximum [Member]
Lessee, Lease, Description [Line Items]
Lessee, Operating Lease, Term of Contract	15 years
Minimum [Member]
Lessee, Lease, Description [Line Items]
Lessee, Operating Lease, Term of Contract	1 year

Leases (Details)

Leases (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Leases [Abstract]
Operating Lease, Cost	$ 5,819	$ 2,798	$ 16,472	$ 8,455
Finance Lease, Interest Expense	25	29	82	92
Finance Lease, Right-of-Use Asset, Amortization	176	166	516	478
Short-term Lease, Cost	1	4	7	14
Lease, Cost	$ 6,021	$ 2,997	$ 17,077	$ 9,039

Leases Cash Flow, Operating Act

Leases Cash Flow, Operating Activities, Lessee (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Leases [Abstract]
Operating Lease, Payments	$ 18,886	$ 8,461
Finance Lease, Interest Payment on Liability	25	29
Right-of-Use Asset Obtained in Exchange for Operating Lease Liability	4,771	1,394
Right-of-Use Asset Obtained in Exchange for Finance Lease Liability	$ 266	$ 373

Leases Assets and Liabilities,

Leases Assets and Liabilities, Lessee (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Leases [Abstract]
Operating Lease, Right-of-Use Asset	$ 76,438	$ 39,847	[1]
Operating Lease, Liability, Current	18,638	9,009
Operating Lease, Liability, Noncurrent	62,902	33,971
Operating Lease, Liability	$ 81,540	$ 42,980
Operating Lease, Weighted Average Remaining Lease Term	6 years 1 month 6 days	5 years 10 months 24 days
Operating Lease, Weighted Average Discount Rate, Percent	4.38%	4.98%
Finance Lease, Right-of-Use Asset	$ 2,327	$ 2,673
Finance Lease, Liability, Current	700	643
Finance Lease, Liability, Noncurrent	1,692	2,067
Finance Lease, Liability	$ 2,392	$ 2,710
Finance Lease, Weighted Average Remaining Lease Term	4 years 10 months 24 days	5 years 7 months 6 days
Finance Lease, Weighted Average Discount Rate, Percent	4.26%	4.28%
[1]December 31, 2021 balances were derived from audited consolidated financial statements.

Leases Maturity (Details)

Leases Maturity (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Leases [Abstract]
Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year	$ 6,129
Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months	20,915
Lessee, Operating Lease, Liability, Payments, Due Year Two	17,157
Lessee, Operating Lease, Liability, Payments, Due Year Three	12,233
Lessee, Operating Lease, Liability, Payments, Due Year Four	10,980
Lessee, Operating Lease, Liability, Payments, Due Year Five	7,638
Lessee, Operating Lease, Liability, Payments, Due after Year Five	16,600
Lessee, Operating Lease, Liability, Payments, Due	91,652
Lessee, Operating Lease, Liability, Undiscounted Excess Amount	(10,112)
Operating Lease, Liability	81,540	$ 42,980
Finance Lease, Liability, Payments, Remainder of Fiscal Year	197
Finance Lease, Liability, Payments, Due Next Twelve Months	790
Finance Lease, Liability, Payments, Due Year Two	524
Finance Lease, Liability, Payments, Due Year Three	317
Finance Lease, Liability, Payments, Due Year Four	217
Finance Lease, Liability, Payments, Due Year Five	189
Finance Lease, Liability, Payments, Due after Year Five	426
Finance Lease, Liability, Payment, Due	2,660
Finance Lease, Liability, Undiscounted Excess Amount	(268)
Finance Lease, Liability	$ 2,392	$ 2,710

Net Income Per Share (Details)

Net Income Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	12,235	12,132
Net (Loss) Income	$ (13,208)	$ 31,081	$ (58,750)	$ 83,210
Weighted average number of common shares outstanding (for basic calculation)	23,908,000	21,214,000	23,828,000	21,189,000
Dilutive securities	0	516,000	0	546,000
Diluted (in shares)	23,908,000	21,730,000	23,828,000	21,735,000
EPS - basic	$ (0.55)	$ 1.47	$ (2.47)	$ 3.93
Diluted (In dollars per share)	$ (0.55)	$ 1.43	$ (2.47)	$ 3.83

Net Income Per Share (Details 1

Net Income Per Share (Details 1) - $ / shares	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Earnings Per Share [Abstract]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	12,235	12,132
Dilutive securities	0	516,000	0	546,000
Diluted (in shares)	23,908,000	21,730,000	23,828,000	21,735,000
Basic (in dollars per share)	$ (0.55)	$ 1.47	$ (2.47)	$ 3.93
Diluted (in dollars per share)	$ (0.55)	$ 1.43	$ (2.47)	$ 3.83

Derivative Financial Instrume_3

Derivative Financial Instruments Foreign Exchange Forward Contracts(Details)	Sep. 30, 2022 USD ($)
Derivative [Line Items]
Derivative, Notional Amount	$ 145,200,000
other currencies
Derivative [Line Items]
Derivative, Notional Amount	3,100,000
Mexico, Pesos
Derivative [Line Items]
Derivative, Notional Amount	31,500,000
Euro Member Countries, Euro
Derivative [Line Items]
Derivative, Notional Amount	27,900,000
Czech Republic, Koruny
Derivative [Line Items]
Derivative, Notional Amount	10,900,000
Japan, Yen
Derivative [Line Items]
Derivative, Notional Amount	12,200,000
United States of America, Dollars
Derivative [Line Items]
Derivative, Notional Amount	26,200,000
Canada, Dollars
Derivative [Line Items]
Derivative, Notional Amount	11,700,000
Australia, Dollars
Derivative [Line Items]
Derivative, Notional Amount	$ 6,800,000

Derivative Financial Instrume_4

Derivative Financial Instruments (Details)	Sep. 30, 2022 USD ($)	Sep. 30, 2022 MXN ($)	Dec. 31, 2021 MXN ($)
Derivative [Line Items]
Foreign Currency Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months	$ 9,900,000
Derivative, Notional Amount	145,200,000
Mexico, Pesos
Derivative [Line Items]
Derivative, Notional Amount	31,500,000
China, Yuan Renminbi
Derivative [Line Items]
Derivative, Notional Amount	15,000,000
United States of America, Dollars
Derivative [Line Items]
Derivative, Notional Amount	$ 26,200,000
Hedge 2 [Member]
Derivative [Line Items]
Derivative, Forward Exchange Rate	21.60	21.60
Derivative Asset, Notional Amount		$ 103,800,000	$ 413,100,000
Hedge 3 [Member] [Member]
Derivative [Line Items]
Derivative, Forward Exchange Rate			24.26

Derivative Financial Instrume_5

Derivative Financial Instruments Interest Rate Swaps (Details)	Sep. 30, 2022 USD ($)
Derivative [Line Items]
Derivative, Notional Amount	$ 145,200,000
Interest Rate Swap | Term Loan A
Derivative [Line Items]
Derivative, Notional Amount	300,000,000
Interest Rate Swap Ending Notional Value	$ 150,000,000
Derivative, Fixed Interest Rate	1.32%
derivative variable rate floor	(0.0015)
Interest Rate Swap | Term Loan B
Derivative [Line Items]
Derivative, Notional Amount	$ 750,000,000
Interest Rate Swap Ending Notional Value	$ 46,900,000
Derivative, Fixed Interest Rate	1.17%
derivative variable rate floor	0.0035

Derivative Financial Instrume_6

Derivative Financial Instruments Derivative Instruments and Hedging Activities - FV of Derivative Instruments Included Within Consolidated Balance Sheet (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Derivatives, Fair Value [Line Items]
Derivative Asset	$ 70,005	$ 1,061
Derivative Liability, Current, Statement of Financial Position [Extensible Enumeration]	Accrued liabilities	Accrued liabilities
Derivative Asset, Current	$ 36,619	$ 1,061
Derivative Asset, Noncurrent	33,386	0
Derivative Liability, Current	$ 1,752	$ 0
Derivative Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]	Other long-term liabilities	Other long-term liabilities
Derivative Liability, Noncurrent	$ 0	$ 1,480
Derivative Liability	$ 1,752	$ 1,480
Derivative Asset, Current, Statement of Financial Position [Extensible Enumeration]	Prepaid expenses and other current assets	Prepaid expenses and other current assets
Derivative Asset, Noncurrent, Statement of Financial Position [Extensible Enumeration]	OTHER ASSETS	OTHER ASSETS
Foreign Exchange Contract
Derivatives, Fair Value [Line Items]
Derivative Asset	$ 11,695	$ 1,061
Derivative Asset, Current	11,695	1,061
Derivative Asset, Noncurrent	0	0
Derivative Liability, Current	1,752	0
Derivative Liability, Noncurrent	0	0
Derivative Liability	1,752	0
Interest Rate Swap
Derivatives, Fair Value [Line Items]
Derivative Asset	58,310	0
Derivative Asset, Current	24,924	0
Derivative Asset, Noncurrent	33,386	0
Derivative Liability, Current	0	0
Derivative Liability, Noncurrent	0	1,480
Derivative Liability	$ 0	$ 1,480

Derivative Financial Instrume_7

Derivative Financial Instruments Derivative Instruments and Hedging Activities - Cash Flow Hedge Activity Included in Accumulated Other Comprehensive Income (Loss) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Other Comprehensive Income (Loss), before Tax	$ 24,584	$ (109)	$ 72,118	$ (70)
Foreign Exchange Contract
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Other Comprehensive Income (Loss), before Tax	3,383	(109)	11,720	(70)
Interest Rate Swap
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Other Comprehensive Income (Loss), before Tax	$ 21,201	$ 0	$ 60,398	$ 0

Derivative Financial Instrume_8

Derivative Financial Instruments Derivative Instruments and Hedging Activities - Amounts Affecting Consolidated Statements of Income (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Derivative Instruments, Gain (Loss) [Line Items]
Foreign Currency Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months	$ 9,900		$ 9,900
Interest Rate Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net	25,600		25,600
Cash Flow Hedging [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Derivative Instruments, Gain Reclassified from Accumulated OCI into Income, Effective Portion	3,995	$ 968
Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net			8,131	$ 2,713
Foreign Exchange Contract | Cash Flow Hedging [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Gain on Discontinuation of Cash Flow Hedge Due to Forecasted Transaction Probable of Not Occurring	462	0	$ 717	0
Derivative Instrument, Gain (Loss) Reclassified from AOCI into Income, Effective Portion, Statement of Income or Comprehensive Income [Extensible Enumeration]			Revenue from Contract with Customer, Excluding Assessed Tax
Foreign Exchange Contract | Trading Revenue | Cash Flow Hedging [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net	1,690	0	$ 2,666	0
Foreign Exchange Contract | Cost of Sales [Member] | Cash Flow Hedging [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net	(3,090)	(968)	$ 4,140	2,713
Derivative Instrument, Gain (Loss) Reclassified from AOCI into Income, Effective Portion, Statement of Income or Comprehensive Income [Extensible Enumeration]			Cost of goods sold
Interest Rate Swap | Cash Flow Hedging [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Derivative Instruments, Loss Reclassified from Accumulated OCI into Income, Effective Portion		$ 0		$ 0
Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net	$ (2,133)		$ 608
Derivative Instrument, Gain (Loss) Reclassified from AOCI into Income, Effective Portion, Statement of Income or Comprehensive Income [Extensible Enumeration]			Interest Expense

Fair Value Measures and Discl_3

Fair Value Measures and Disclosures (Details) $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2022 USD ($)	Sep. 30, 2022 USD ($)	Jun. 30, 2022 USD ($)	Mar. 31, 2022 USD ($)	Jan. 06, 2022 USD ($)	Dec. 31, 2021 USD ($)	Jun. 30, 2021 USD ($)	Mar. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
CONTINGENT EARN-OUT LIABILITY	$ 26,242	$ 26,242	$ 30,409	$ 57,701		$ 2,589
Contingent Consideration, Gross ST	1,000
Contingent Consideration, Gross LT	$ 1,500
Ownership requirement for Earnout Payment	0.500	0.500
Liability
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
contingent consideration gross		$ 6,000
CONTINGENT EARN-OUT LIABILITY	$ 2,600	2,600
Pursuit Vascular, Inc. [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
contingent consideration gross		50,000
CONTINGENT EARN-OUT LIABILITY	26,300	26,300					$ 26,300	$ 26,300	$ 26,300
SmithsMedical
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
contingent consideration gross	100,000
Business Combination, Contingent Consideration, Liability	21,800	21,800			$ 53,500
Foreign Infusion System Supplier
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
contingent consideration gross	2,500
Contingent Consideration, Gross ST	1,000
Contingent Consideration, Gross LT	1,500
Business Combination, Contingent Consideration, Liability	$ 1,800	$ 1,800

Fair Value Measures and Discl_4

Fair Value Measures and Disclosures Liabilities Recurring Basis Unobservable Input Reconciliation Pursuit (Details) - USD ($) $ in Thousands	3 Months Ended					9 Months Ended
	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2021	Mar. 31, 2021	Sep. 30, 2022	Dec. 31, 2021	Dec. 31, 2020
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
CONTINGENT EARN-OUT LIABILITY	$ 26,242	$ 30,409	$ 57,701			$ 26,242	$ 2,589
Business Combination, Consideration Transferred, Liabilities Incurred			55,158
Currency translation on earn-out	(108)	(98)	(46)
Pursuit Vascular, Inc. [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
CONTINGENT EARN-OUT LIABILITY	26,300			$ 26,300	$ 26,300	26,300		$ 26,300
Fair Value, Liability, Recurring Basis, Still Held, Unrealized Gain (Loss)				$ 0	$ 0
SmithsMedical
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Business Combination, Consideration Transferred, Liabilities Incurred			53,500			$ 53,520
Fair Value, Liability, Recurring Basis, Still Held, Unrealized Gain (Loss)	$ (4,059)	$ (27,194)
Foreign Infusion System Supplier
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Business Combination, Consideration Transferred, Liabilities Incurred			$ 1,600

Fair Value Measures and Discl_5

Fair Value Measures and Disclosures Liabilities Recurring Basis Unobservable Input Reconciliation Hospira (Details) - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
CONTINGENT EARN-OUT LIABILITY				$ 26,242	$ 30,409	$ 57,701	$ 2,589
Pursuit Vascular, Inc. [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
CONTINGENT EARN-OUT LIABILITY		$ 26,300	$ 26,300	$ 26,300				$ 26,300
Fair Value, Liability, Recurring Basis, Still Held, Unrealized Gain (Loss)		$ 0	$ 0
Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers out of Level 3	$ (26,300)
International Distributor
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
CONTINGENT EARN-OUT LIABILITY	$ 3,100

Fair Value Measures and Discl_6

Fair Value Measures and Disclosures Liability Measurement Inputs (Details)	Sep. 30, 2022	Jan. 06, 2022	Sep. 30, 2021
Pursuit Vascular, Inc. [Member] | MeasurementinputadjustedEBITDAvolatility [Domain]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Business Combination, Contingent Consideration, Liability, Measurement Input			0.2500
Pursuit Vascular, Inc. [Member] | Measurement Input, Discount Rate [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Business Combination, Contingent Consideration, Liability, Measurement Input			0.1250
Pursuit Vascular, Inc. [Member] | Measurement Input, Risk Free Interest Rate [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Business Combination, Contingent Consideration, Liability, Measurement Input			0.0009
Pursuit Vascular, Inc. [Member] | Measurement Input, Market Price of Risk [Domain]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Business Combination, Contingent Consideration, Liability, Measurement Input			0.0310
SmithsMedical | Measurement Input, Risk Free Interest Rate [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Business Combination, Contingent Consideration, Liability, Measurement Input	0.0418	0.0131
SmithsMedical | Measurement Input, Price Volatility
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Business Combination, Contingent Consideration, Liability, Measurement Input	0.4200	0.3700

Fair Value Measures and Discl_7

Fair Value Measures and Disclosures Assets and Liabilities by Balance Sheet Grouping (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Short-term investment securities	$ 2,919	$ 14,420	[1]
Long-term investment securities	1,831	4,620
Assets, Fair Value Disclosure	74,755	20,101
Interest Rate Derivative Liabilities, at Fair Value	$ 0	$ 1,480
Derivative Asset, Current, Statement of Financial Position [Extensible Enumeration]	Prepaid expenses and other current assets	Prepaid expenses and other current assets
Derivative Asset, Noncurrent, Statement of Financial Position [Extensible Enumeration]	OTHER ASSETS	OTHER ASSETS
Derivative Liability, Current, Statement of Financial Position [Extensible Enumeration]	Accrued liabilities	Accrued liabilities
Derivative Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]	Other long-term liabilities	Other long-term liabilities
current
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Foreign Currency Contract, Asset, Fair Value Disclosure	$ 11,695	$ 1,061
Interest Rate Derivative Assets, at Fair Value	24,924
Foreign Currency Contracts, Liability, Fair Value Disclosure	1,752
noncurrent
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Foreign Currency Contract, Asset, Fair Value Disclosure	0
Interest Rate Derivative Assets, at Fair Value	33,386
Interest Rate Derivative Liabilities, at Fair Value		1,480
Corporate Bond Securities
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Short-term investment securities	1,511
Long-term investment securities	1,333
US Treasury Securities
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Short-term investment securities	1,408
US Government Debt Securities
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term investment securities	498
Earn-out liability [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Nonfinancial Liabilities Fair Value Disclosure	25,942	2,589
Liabilities, Total [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Nonfinancial Liabilities Fair Value Disclosure		4,069
Financial Liabilities Fair Value Disclosure	27,994
Earn-out liability ST
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Nonfinancial Liabilities Fair Value Disclosure	300
Prepaid Expenses and Other Current Assets [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Foreign Currency Contract, Asset, Fair Value Disclosure	11,695	1,061
Interest Rate Derivative Assets, at Fair Value	24,924	0
Fair Value, Inputs, Level 1 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Short-term investment securities		0
Long-term investment securities		0
Assets, Fair Value Disclosure	1,408	0
Fair Value, Inputs, Level 1 [Member] | current
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Foreign Currency Contract, Asset, Fair Value Disclosure	0	0
Interest Rate Derivative Assets, at Fair Value	0
Foreign Currency Contracts, Liability, Fair Value Disclosure	0
Fair Value, Inputs, Level 1 [Member] | noncurrent
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Foreign Currency Contract, Asset, Fair Value Disclosure	0
Interest Rate Derivative Assets, at Fair Value	0
Interest Rate Derivative Liabilities, at Fair Value		0
Fair Value, Inputs, Level 1 [Member] | Corporate Bond Securities
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Short-term investment securities	0
Long-term investment securities	0
Fair Value, Inputs, Level 1 [Member] | US Treasury Securities
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Short-term investment securities	1,408
Fair Value, Inputs, Level 1 [Member] | US Government Debt Securities
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term investment securities	0
Fair Value, Inputs, Level 1 [Member] | Earn-out liability [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Nonfinancial Liabilities Fair Value Disclosure	0	0
Fair Value, Inputs, Level 1 [Member] | Liabilities, Total [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Nonfinancial Liabilities Fair Value Disclosure		0
Financial Liabilities Fair Value Disclosure	0
Fair Value, Inputs, Level 1 [Member] | ST Earnout Liability
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Nonfinancial Liabilities Fair Value Disclosure	0
Fair Value, Inputs, Level 2 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Short-term investment securities		14,420
Long-term investment securities		4,620
Assets, Fair Value Disclosure	73,347	20,101
Fair Value, Inputs, Level 2 [Member] | current
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Foreign Currency Contract, Asset, Fair Value Disclosure	11,695	1,061
Interest Rate Derivative Assets, at Fair Value	24,924
Foreign Currency Contracts, Liability, Fair Value Disclosure	1,752
Fair Value, Inputs, Level 2 [Member] | noncurrent
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Foreign Currency Contract, Asset, Fair Value Disclosure	0
Interest Rate Derivative Assets, at Fair Value	33,386
Interest Rate Derivative Liabilities, at Fair Value		1,480
Fair Value, Inputs, Level 2 [Member] | Corporate Bond Securities
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Short-term investment securities	1,511
Long-term investment securities	1,333
Fair Value, Inputs, Level 2 [Member] | US Treasury Securities
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Short-term investment securities	0
Fair Value, Inputs, Level 2 [Member] | US Government Debt Securities
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term investment securities	498
Fair Value, Inputs, Level 2 [Member] | Earn-out liability [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Nonfinancial Liabilities Fair Value Disclosure	0	0
Fair Value, Inputs, Level 2 [Member] | Liabilities, Total [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Nonfinancial Liabilities Fair Value Disclosure		1,480
Financial Liabilities Fair Value Disclosure	1,752
Fair Value, Inputs, Level 2 [Member] | ST Earnout Liability
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Nonfinancial Liabilities Fair Value Disclosure	0
Fair Value, Inputs, Level 3 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Short-term investment securities		0
Long-term investment securities		0
Assets, Fair Value Disclosure	0	0
Fair Value, Inputs, Level 3 [Member] | current
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Foreign Currency Contract, Asset, Fair Value Disclosure	0	0
Interest Rate Derivative Assets, at Fair Value	0
Foreign Currency Contracts, Liability, Fair Value Disclosure	0
Fair Value, Inputs, Level 3 [Member] | noncurrent
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Foreign Currency Contract, Asset, Fair Value Disclosure	0
Interest Rate Derivative Assets, at Fair Value	0
Interest Rate Derivative Liabilities, at Fair Value		0
Fair Value, Inputs, Level 3 [Member] | Corporate Bond Securities
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Short-term investment securities	0
Long-term investment securities	0
Fair Value, Inputs, Level 3 [Member] | US Treasury Securities
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Short-term investment securities	0
Fair Value, Inputs, Level 3 [Member] | US Government Debt Securities
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term investment securities	0
Fair Value, Inputs, Level 3 [Member] | Earn-out liability [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Nonfinancial Liabilities Fair Value Disclosure	25,942	2,589
Fair Value, Inputs, Level 3 [Member] | Liabilities, Total [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Nonfinancial Liabilities Fair Value Disclosure		$ 2,589
Financial Liabilities Fair Value Disclosure	26,242
Fair Value, Inputs, Level 3 [Member] | ST Earnout Liability
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Nonfinancial Liabilities Fair Value Disclosure	$ 300
[1]December 31, 2021 balances were derived from audited consolidated financial statements.

Investment Securities (Details)

Investment Securities (Details) $ in Millions	9 Months Ended
	Sep. 30, 2022 USD ($)
Investments, Debt and Equity Securities [Abstract]
Gain (Loss) on Sale of Investments	$ 0
Proceeds from Sale and Maturity of Other Investments	$ 19

Investment Securities Table (De

Investment Securities Table (Details) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended	12 Months Ended
	Mar. 31, 2022	Sep. 30, 2022	Dec. 31, 2021
Debt Securities, Available-for-sale [Line Items]
Debt Securities, Available-for-sale, Amortized Cost		$ 4,750	$ 19,040
Debt Securities, Available-for-sale, Unrealized Loss		0	0
Short-term investment securities		2,919	14,420	[1]
Long-term investment securities		1,831	4,620
Debt Securities, Available-for-sale		4,750	19,040
Corporate Debt Securities
Debt Securities, Available-for-sale [Line Items]
Debt Securities, Available-for-sale, Amortized Cost, Current		1,511	14,420
Debt Securities, Available-for-sale, Noncurrent		1,333	4,620
Debt Securities, Available-for-sale, Unrealized Loss	$ 0	0	0
Short-term investment securities		1,511	14,420
Long-term investment securities		1,333	$ 4,620
US Treasury Securities
Debt Securities, Available-for-sale [Line Items]
Debt Securities, Available-for-sale, Amortized Cost, Current		1,408
Debt Securities, Available-for-sale, Unrealized Loss		0
Short-term investment securities		1,408
US Government Debt Securities
Debt Securities, Available-for-sale [Line Items]
Debt Securities, Available-for-sale, Noncurrent		498
Debt Securities, Available-for-sale, Unrealized Loss		0
Long-term investment securities		$ 498
[1]December 31, 2021 balances were derived from audited consolidated financial statements.

Equity Method Investments (Deta

Equity Method Investments (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Equity Securities without Readily Determinable Fair Value [Line Items]
Equity Method Investment, Aggregate Cost	$ 3,300
Equity Method Investments	$ 3,188	$ 3,238
Non Public Company
Equity Securities without Readily Determinable Fair Value [Line Items]
Equity Method Investment, Ownership Percentage	20%

Prepaids and Other Current As_3

Prepaids and Other Current Assets Prepaids and Other Assets (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Prepaid Expense and Other Assets [Abstract]
Other Prepaid Expense, Current	$ 22,738	$ 14,763
Prepaid vendor expenses	2,641	0
Deferred Costs and Other Assets	3,775	12,746
Prepaid insurance and property taxes	14,019	6,310
Prepaid Taxes	2,946	4,156
Deferred tax charge	4,452	4,241
Deposit Assets	1,312	1,343
Other Assets, Current	3,355	1,934
Prepaid expenses and other current assets	94,283	46,847	[1]
Interest Receivable	2,426	293
Prepaid Expenses and Other Current Assets [Member]
Prepaid Expense and Other Assets [Abstract]
Foreign Currency Contract, Asset, Fair Value Disclosure	11,695	1,061
Interest Rate Derivative Assets, at Fair Value	24,924	0
Derivative [Line Items]
Foreign Currency Contract, Asset, Fair Value Disclosure	$ 11,695	$ 1,061
[1]December 31, 2021 balances were derived from audited consolidated financial statements.

Other Assets Noncurrent(Details

Other Assets Noncurrent(Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Derivative [Line Items]
Derivative Asset, Noncurrent	$ 33,386	$ 0
Lessor, Operating Lease, Payments to be Received	27,024	25,941
Spare parts	36,937	28,538
Equity Method Investments	3,188	3,238
Debt Issuance Costs, Noncurrent, Net	5,586	2,827
Finance Lease, Right-of-Use Asset	2,327	2,673
Derivative Asset, Noncurrent	33,386	0
Other Assets, Miscellaneous, Noncurrent	2,156	526
OTHER ASSETS	110,604	63,743	[1]
Interest Rate Swap
Derivative [Line Items]
Derivative Asset, Noncurrent	33,386	0
Derivative Asset, Noncurrent	$ 33,386	$ 0
[1]December 31, 2021 balances were derived from audited consolidated financial statements.

Inventories (Details)

Inventories (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Inventory Disclosure [Abstract]
Inventory, Raw Materials, Net of Reserves	$ 264,518	$ 135,528
Inventory, Work in Process, Net of Reserves	71,367	36,490
Inventory, Finished Goods, Net of Reserves	289,383	118,217
Total	$ 625,268	$ 290,235	[1]
[1]December 31, 2021 balances were derived from audited consolidated financial statements.

Property and Equipment (Details

Property and Equipment (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Property, Plant and Equipment [Line Items]
Total property and equipment, cost	$ 1,154,481	$ 905,104
Accumulated depreciation	(498,098)	(436,739)
Net property and equipment	656,383	468,365	[1]
Machinery and Equipment, Gross	409,349	321,078
Furniture and Fixtures, Gross	29,110	7,670
Construction in Progress, Gross	147,099	72,153
Land, Buildings and Improvements [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment, cost	272,426	243,377
Molds [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment, cost	75,874	60,463
Computer Equipment and Software [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment, cost	114,378	102,979
Instruments Placed with Customers [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment, cost	$ 106,245	$ 97,384
[1]December 31, 2021 balances were derived from audited consolidated financial statements.

Property and Equipment Text (De

Property and Equipment Text (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Property, Plant and Equipment [Abstract]
Depreciation	$ 23,000,000	$ 16,400,000	$ 69,400,000	$ 49,100,000

Goodwill and Intangible Asset_3

Goodwill and Intangible Assets Goodwill Table (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2022	Dec. 31, 2021	[1]
Goodwill and Intangible Assets Disclosure [Abstract]
GOODWILL	$ 1,369,717	$ 43,439
Goodwill, Acquired During Period	1,449,977
Goodwill, Purchase Accounting Adjustments	(7,128)
Goodwill, Foreign Currency Translation Gain (Loss)	$ (116,571)
[1]December 31, 2021 balances were derived from audited consolidated financial statements.

Goodwill and Intangible Asset_4

Goodwill and Intangible Assets Intangibles Table (Details) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Mar. 31, 2022	Sep. 30, 2022	Dec. 31, 2021
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross		$ 1,209,357	$ 275,835
Finite-Lived Intangible Assets, Accumulated Amortization		218,744	112,882
Finite-Lived Intangible Assets, Net		990,613	162,953
Indefinite-lived Intangible Assets (Excluding Goodwill)		30,045	25,358
Intangible Assets, Gross (Excluding Goodwill)		1,239,402	301,193
INTANGIBLE ASSETS, net		$ 1,020,658	188,311	[1]
Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Asset, Useful Life	10 years	10 years
Finite-Lived Intangible Assets, Gross		$ 29,301	27,429
Finite-Lived Intangible Assets, Accumulated Amortization		18,135	16,764
Finite-Lived Intangible Assets, Net		$ 11,166	10,665
Customer Contracts [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Asset, Useful Life	12 years	12 years
Finite-Lived Intangible Assets, Gross		$ 9,909	10,412
Finite-Lived Intangible Assets, Accumulated Amortization		6,339	6,196
Finite-Lived Intangible Assets, Net		$ 3,570	4,216
Customer-Related Intangible Assets [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Asset, Useful Life	9 years	8 years
Finite-Lived Intangible Assets, Gross		$ 560,691	57,316
Finite-Lived Intangible Assets, Accumulated Amortization		85,081	33,004
Finite-Lived Intangible Assets, Net		$ 475,610	24,312
Trademarks [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Asset, Useful Life	4 years	1 year
Finite-Lived Intangible Assets, Gross		$ 5,425	425
Finite-Lived Intangible Assets, Accumulated Amortization		5,425	425
Finite-Lived Intangible Assets, Net		$ 0	0
Trade Names [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Asset, Useful Life	15 years	15 years
Finite-Lived Intangible Assets, Gross		$ 18,244	18,260
Finite-Lived Intangible Assets, Accumulated Amortization		5,643	4,731
Finite-Lived Intangible Assets, Net		$ 12,601	13,529
Developed Technology Rights [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Asset, Useful Life	13 years	10 years
Finite-Lived Intangible Assets, Gross		$ 576,687	152,893
Finite-Lived Intangible Assets, Accumulated Amortization		93,490	49,406
Finite-Lived Intangible Assets, Net		$ 483,197	103,487
Noncompete Agreements [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Asset, Useful Life	3 years	3 years
Finite-Lived Intangible Assets, Gross		$ 9,100	9,100
Finite-Lived Intangible Assets, Accumulated Amortization		4,631	2,356
Finite-Lived Intangible Assets, Net		$ 4,469	$ 6,744
[1]December 31, 2021 balances were derived from audited consolidated financial statements.

Goodwill and Intangible Asset_5

Goodwill and Intangible Assets Text (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization of Intangible Assets	$ 35,600,000	$ 5,800,000	$ 108,900,000	$ 17,400,000

Goodwill and Intangible Asset_6

Goodwill and Intangible Assets 5-Year Amortization (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months	$ 33,624
Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months	132,368
Finite-Lived Intangible Assets, Amortization Expense, Year Two	131,729
Finite-Lived Intangible Assets, Amortization Expense, Year Four	123,901
Finite-Lived Intangible Assets, Amortization Expense, Year Five	123,502
Finite-Lived Intangible Assets, Amortization Expense, Year Five	115,491
Finite-Lived Intangible Assets, Amortization Expense, after Year Five	329,998
Finite-Lived Intangible Assets, Net	$ 990,613	$ 162,953

Accrued Liabilities (Details)

Accrued Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Jan. 06, 2022	Dec. 31, 2021
Accrued Liabilities [Abstract]
Salaries and benefits	$ 49,409		$ 27,304
Incentive compensation	24,388		33,107
Operating Lease, Liability, Current	18,638		9,009
Sales taxes	6,507		1,980
Restructuring accrual	6,767		664
UnfavorablecontractliabilityST	31,183		12,646
Accrued other taxes	4,415		4,337
Accrued Professional Fees	8,694		773
Legal accrual	4,240		3,897
Distribution Fees	25,326		5,645
Warranties and returns	3,059		532
Field service corrective action	24,857		0
Accrued freight	14,234		9,194
Derivative Liability, Current	1,752		0
Other	9,424		8,099
Accrued liabilities	244,303		118,195	[1]
Liability, Defined Benefit Plan, Current	2,527		0
Accrued audit fees	6,095		1,008
Derivative [Line Items]
Derivative Liability, Current	1,752		0
Product Liability Contingency [Line Items]
Product Liability Accrual, Component Amount	47,500	$ 55,100
Interest Payable	2,788		0
Foreign Exchange
Accrued Liabilities [Abstract]
Derivative Liability, Current	1,752		0
Derivative [Line Items]
Derivative Liability, Current	$ 1,752		$ 0
[1]December 31, 2021 balances were derived from audited consolidated financial statements.

Accrued Liabilities Long-term l

Accrued Liabilities Long-term liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Jan. 06, 2022	Dec. 31, 2021
Accrued Liabilities [Abstract]
Operating Lease, Liability, Noncurrent	$ 62,902		$ 33,971
Accrued Employee Benefits	5,958		1,369
Accrued Rent	1,030		1,262
Interest Rate Derivative Liabilities, at Fair Value	0		1,480
Derivative Liability, Noncurrent	0		1,480
Finance Lease, Liability, Noncurrent	1,692		2,067
Other Accrued Liabilities, Noncurrent	3,073		1,681
OTHER LONG-TERM LIABILITIES	119,251		41,830
Product Liability Accrual, Component Amount	47,500	$ 55,100
Product Liability Contingency [Line Items]
Product Liability Accrual, Component Amount	47,500	$ 55,100
Contract with Customer, Liability, Noncurrent	21,976		0
Derivative [Line Items]
Derivative Liability, Noncurrent	0		1,480
Long Term
Accrued Liabilities [Abstract]
Product Liability Accrual, Component Amount	22,620		0
Product Liability Contingency [Line Items]
Product Liability Accrual, Component Amount	$ 22,620		$ 0

Income Taxes Effective tax rate

Income Taxes Effective tax rate (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Business Acquisition, Contingent Consideration [Line Items]
Change in fair value of contingent earn-out	$ (4,059,000)	$ 0	$ (31,253,000)	$ 0
Effective Income Tax Rate	38%	18%	37%	17%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent			21%	21%
Share-based Payment Arrangement, Expense, Tax Benefit	$ 1,500,000	$ 1,100,000	$ 4,100,000	$ 3.3
contingent consideration, tax expense	0		0
SmithsMedical
Business Acquisition, Contingent Consideration [Line Items]
Change in fair value of contingent earn-out	$ (4,100,000)		$ (31,300,000)

Long-Term Obligations (Details)

Long-Term Obligations (Details) $ in Thousands	3 Months Ended
	Sep. 30, 2022 USD ($)
Debt Instrument [Line Items]
TotalSeniorSecuredCreditFacility	$ 2,200,000
Long-term Debt, Gross	1,679,750
Revolver Sub limits	50,000
Debt Issuance Costs, Gross	37,800
Leverage Ratio Calculation Ceiling Subtracted Amount	500,000
Term Loan A
Debt Instrument [Line Items]
Proceeds from Issuance of Debt	850,000
Long-term Debt, Gross	834,000
Debt Issuance Costs, Gross	15,800
Long-term Debt	$ 834,200
Debt Instrument, Maturity Date	Jan. 06, 2027
Term Loan B
Debt Instrument [Line Items]
Proceeds from Issuance of Debt	$ 850,000
Long-term Debt, Gross	845,750
Debt Issuance Costs, Gross	13,400
Long-term Debt	$ 836,600
Debt Instrument, Maturity Date	Jan. 06, 2029
Revolving Credit Facility
Debt Instrument [Line Items]
Long-term Debt, Gross	$ 500,000
Debt Issuance Costs, Gross	$ 8,700

Long-Term Obligations Interest

Long-Term Obligations Interest Rate Terms (Details)	3 Months Ended
	Sep. 30, 2022
Debt Disclosure [Abstract]
Interest Percentage Added to Federal Funds Rate	0.0050
Interest Percentage Added to Base Rate	0.0100
Ter SOFR Interest Rate % Adjustment for Base Rate Loans	0.0010
Line of Credit Facility, Commitment Fee Percentage	0.25%
Applicable Margin Based on Leverage Ratio [Line Items]
Line of Credit Facility, Commitment Fee Percentage	0.25%
Maximum [Member]
Debt Disclosure [Abstract]
Term SOFR Adjustment Interest Rate Adjustment Term SOFR Loans	0.0025
Applicable Margin Based on Leverage Ratio [Line Items]
Term SOFR Adjustment Interest Rate Adjustment Term SOFR Loans	0.0025
Minimum [Member]
Debt Disclosure [Abstract]
Term SOFR Adjustment Interest Rate Adjustment Term SOFR Loans	0.0010
Applicable Margin Based on Leverage Ratio [Line Items]
Term SOFR Adjustment Interest Rate Adjustment Term SOFR Loans	0.0010
greaterthan 4to1
Debt Disclosure [Abstract]
Line of Credit Facility, Commitment Fee Percentage	0.35%
Applicable Margin Based on Leverage Ratio [Line Items]
Line of Credit Facility, Commitment Fee Percentage	0.35%
lessthan4to1butgreaterthan3to1
Debt Disclosure [Abstract]
Line of Credit Facility, Commitment Fee Percentage	0.30%
Applicable Margin Based on Leverage Ratio [Line Items]
Line of Credit Facility, Commitment Fee Percentage	0.30%
lessthanorequal3to1butgreaterthan2point5to1
Debt Disclosure [Abstract]
Line of Credit Facility, Commitment Fee Percentage	0.25%
Applicable Margin Based on Leverage Ratio [Line Items]
Line of Credit Facility, Commitment Fee Percentage	0.25%
lessthanorequalto2point5to1butgreaterthan2to1
Debt Disclosure [Abstract]
Line of Credit Facility, Commitment Fee Percentage	0.20%
Applicable Margin Based on Leverage Ratio [Line Items]
Line of Credit Facility, Commitment Fee Percentage	0.20%
lessthanorequalto2to1
Debt Disclosure [Abstract]
Line of Credit Facility, Commitment Fee Percentage	0.15%
Applicable Margin Based on Leverage Ratio [Line Items]
Line of Credit Facility, Commitment Fee Percentage	0.15%
Term Loan A
Debt Disclosure [Abstract]
Applicable Margin Base Rate Loans	0.0075
Applicable Margin Term SOFR Loans	0.0175
Applicable Margin Based on Leverage Ratio [Line Items]
Applicable Margin Base Rate Loans	0.0075
Applicable Margin Term SOFR Loans	0.0175
Term Loan A | greaterthan 4to1
Debt Disclosure [Abstract]
Applicable Margin Base Rate Loans	0.0125
Applicable Margin Term SOFR Loans	0.0225
Applicable Margin Based on Leverage Ratio [Line Items]
Applicable Margin Base Rate Loans	0.0125
Applicable Margin Term SOFR Loans	0.0225
Term Loan A | lessthan4to1butgreaterthan3to1
Debt Disclosure [Abstract]
Applicable Margin Base Rate Loans	0.0100
Applicable Margin Term SOFR Loans	0.0200
Applicable Margin Based on Leverage Ratio [Line Items]
Applicable Margin Base Rate Loans	0.0100
Applicable Margin Term SOFR Loans	0.0200
Term Loan A | lessthanorequal3to1butgreaterthan2point5to1
Debt Disclosure [Abstract]
Applicable Margin Base Rate Loans	0.0075
Applicable Margin Term SOFR Loans	0.0175
Applicable Margin Based on Leverage Ratio [Line Items]
Applicable Margin Base Rate Loans	0.0075
Applicable Margin Term SOFR Loans	0.0175
Term Loan A | lessthanorequalto2point5to1butgreaterthan2to1
Debt Disclosure [Abstract]
Applicable Margin Base Rate Loans	0.0050
Applicable Margin Term SOFR Loans	0.0150
Applicable Margin Based on Leverage Ratio [Line Items]
Applicable Margin Base Rate Loans	0.0050
Applicable Margin Term SOFR Loans	0.0150
Term Loan A | lessthanorequalto2to1
Debt Disclosure [Abstract]
Applicable Margin Base Rate Loans	0.0025
Applicable Margin Term SOFR Loans	0.0125
Applicable Margin Based on Leverage Ratio [Line Items]
Applicable Margin Base Rate Loans	0.0025
Applicable Margin Term SOFR Loans	0.0125
Term Loan B
Debt Disclosure [Abstract]
Applicable Margin Base Rate Loans	0.015
Applicable Margin Term SOFR Loans	0.025
Applicable Margin Based on Leverage Ratio [Line Items]
Applicable Margin Base Rate Loans	0.015
Applicable Margin Term SOFR Loans	0.025
Term Loan B | greaterthan2point75to1
Debt Disclosure [Abstract]
Applicable Margin Base Rate Loans	0.0150
Applicable Margin Term SOFR Loans	0.0250
Applicable Margin Based on Leverage Ratio [Line Items]
Applicable Margin Base Rate Loans	0.0150
Applicable Margin Term SOFR Loans	0.0250
Term Loan B | lessthan2point75to1
Debt Disclosure [Abstract]
Applicable Margin Base Rate Loans	0.0125
Applicable Margin Term SOFR Loans	0.0225
Applicable Margin Based on Leverage Ratio [Line Items]
Applicable Margin Base Rate Loans	0.0125
Applicable Margin Term SOFR Loans	0.0225

Long-Term Obligations Terminate

Long-Term Obligations Terminated Credit Agreement (Details) $ in Millions	9 Months Ended
	Sep. 30, 2022 USD ($)
Debt Disclosure [Abstract]
Line of Credit Facility, Maximum Borrowing Capacity	$ 150
Line of Credit Facility, Expiration Date	Nov. 08, 2022
Line of Credit, Current	$ 0

Long-Term Obligations Table (De

Long-Term Obligations Table (Details) - USD ($)	3 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Debt Instrument [Line Items]
Long-term Debt, Gross	$ 1,679,750,000
Line of Credit Facility, Fair Value of Amount Outstanding	0
Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net	(25,526,000)
Debt, Long-term and Short-term, Combined Amount	1,654,224,000
Debt, Current	24,375,000
Long-term Debt, Excluding Current Maturities	1,629,849,000	$ 0
Revolving Credit Facility
Debt Instrument [Line Items]
Long-term Debt, Gross	$ 500,000,000
Debt Instrument, Interest Rate During Period	0%
Term Loan A
Debt Instrument [Line Items]
Long-term Debt, Gross	$ 834,000,000
Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net	$ 13,400,000
Debt Instrument, Interest Rate During Period	3.39%
Term Loan B
Debt Instrument [Line Items]
Long-term Debt, Gross	$ 845,750,000
Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net	$ 12,200,000
Debt Instrument, Interest Rate During Period	3.98%

Long-Term Obligations Schedule

Long-Term Obligations Schedule of Maturities (Details) $ in Thousands	Sep. 30, 2022 USD ($)
LOng-Term Obligations Disclosure [Abstract]
Long-Term Debt, Maturity, Remainder of Fiscal Year	$ 2,125
Long-Term Debt, Maturity, Year One	29,750
Long-Term Debt, Maturity, Year Two	51,000
Long-Term Debt, Maturity, Year Three	51,000
Long-Term Debt, Maturity, Year Four	72,250
Long-Term Debt, Maturity, Year Five	672,500
Long-Term Debt, Maturity, after Year Five	801,125
Long-term Debt, Gross	$ 1,679,750

Long-Term Obligations Interes_2

Long-Term Obligations Interest Expense (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Debt Disclosure [Abstract]
Interest Expense, Debt, Excluding Amortization	$ 19,228,000	$ 0	$ 41,868,000	$ 0
Amortization of Debt Issuance Costs and Discounts	1,758,000	72,000	5,200,000	216,000
Line of Credit Facility, Commitment Fee Amount	334,000	58,000	994,000	171,000
Interest Expense, Debt	$ 21,320,000	$ 130,000	$ 48,062,000	$ 387,000

Long-Term Obligations Principal

Long-Term Obligations Principal Payment (Details)	3 Months Ended	9 Months Ended
	Sep. 30, 2022 USD ($)	Sep. 30, 2022 USD ($)
Debt Disclosure [Abstract]
Term A principal payment % First 2 Years	0.0250	0.0250
Term A Principal Payment % Year 3 and 4	0.0500	0.0500
Term A Principal Payment % in Year 5	0.0750	0.0750
Term Loan B Principal Payment %	0.0025	0.0025
Debt Instrument, Periodic Payment, Principal	$ 16,000,000	$ 20,300,000

Commitments and Contingencies C

Commitments and Contingencies Contingency (Details) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2022	Jan. 06, 2022
Business Acquisition, Contingent Consideration [Line Items]
Contingent Consideration, Gross ST	$ 1,000
Contingent Consideration, Gross LT	1,500
Product Liability Accrual, Component Amount	47,500	$ 47,500	$ 55,100
SmithsMedical
Business Acquisition, Contingent Consideration [Line Items]
contingent consideration gross	100,000
Business Combination, Contingent Consideration, Liability	21,800	21,800	$ 53,500
Foreign Infusion System Supplier
Business Acquisition, Contingent Consideration [Line Items]
contingent consideration gross	2,500
Contingent Consideration, Gross ST	1,000
Contingent Consideration, Gross LT	1,500
Business Combination, Contingent Consideration, Liability	1,800	1,800
International Distributor
Business Acquisition, Contingent Consideration [Line Items]
contingent consideration gross		6,000
Business Combination, Contingent Consideration, Liability	$ 2,600	$ 2,600

Collaborative and Other Arran_2

Collaborative and Other Arrangements (Details) $ in Millions	Sep. 30, 2022 USD ($)
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Purchase Commitment, Remaining Minimum Amount Committed	$ 29.6

Equity (Details)

Equity (Details) $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2022 USD ($)	Sep. 30, 2022 USD ($) shares	Sep. 30, 2021 USD ($) shares
Equity [Abstract]
Treasury Stock Purchase Plan	$ 100,000	$ 100,000
Stock Repurchase Program, Remaining Authorized Repurchase Amount	$ 100,000	$ 100,000
Share-based Payment Arrangement, Shares Withheld for Tax Withholding Obligation | shares		45,370	39,371
Payment, Tax Withholding, Share-based Payment Arrangement		$ 10,541	$ 8,109
Smiths Group Ownership % Acquisition Shares Issued	0.105	0.105
Smiths Group Ownership % Required for Board Representation	0.050

Equity Accumulated Other Compre

Equity Accumulated Other Comprehensive Income (Loss) (Details) - USD ($) $ in Thousands	3 Months Ended						9 Months Ended
	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021		Dec. 31, 2020
Accumulated Other Comprehensive Income (Loss) [Line Items]
Accumulated other comprehensive loss	$ (165,682)	$ (92,275)	$ (628)	$ (15,118)	$ (8,951)	$ (9,913)	$ (165,682)	$ (15,118)	$ (19,269)	[1]	$ (1,522)
Other Comprehensive Income (Loss), before Reclassifications, Net of Tax	(71,538)	(89,546)	20,851	(5,431)	1,649	(7,752)
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax	(1,869)	(2,101)	(2,210)	(736)	(687)	(639)
Other Comprehensive income (loss), net of Tax	(73,407)	(91,647)	18,641	(6,167)	962	(8,391)	(146,413)	(13,596)
Accumulated Foreign Currency Adjustment Attributable to Parent [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Accumulated other comprehensive loss	(214,345)	(123,796)	(23,991)	(15,897)	(10,537)	(11,839)	(214,345)	(15,897)	(19,045)		(4,381)
Other Comprehensive Income (Loss), before Reclassifications, Net of Tax	(90,549)	(99,805)	(4,946)	(5,360)	1,302	(7,458)
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax	0	0	0	0	0	0
Other Comprehensive income (loss), net of Tax	(90,549)	(99,805)	(4,946)	(5,360)	1,302	(7,458)
Accumulated Net Gain (Loss) from Cash Flow Hedges Attributable to Parent [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Accumulated other comprehensive loss	48,394	31,479	23,335	668	1,487	1,839	48,394	668	(237)		2,784
Other Comprehensive Income (Loss), before Reclassifications, Net of Tax	18,784	10,245	25,782	(83)	335	(306)
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax	(1,869)	(2,101)	(2,210)	(736)	(687)	(639)
Other Comprehensive income (loss), net of Tax	16,915	8,144	23,572	(819)	(352)	(945)
Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Accumulated other comprehensive loss	269	42	28	111	99	87	$ 269	$ 111	$ 13		$ 75
Other Comprehensive Income (Loss), before Reclassifications, Net of Tax	227	14	15	12	12	12
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax	0	0	0	0	0	0
Other Comprehensive income (loss), net of Tax	$ 227	$ 14		$ 12	$ 12	$ 12
Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent			$ 15
[1]December 31, 2021 balances were derived from audited consolidated financial statements.